521 lines
405 KiB
Text
521 lines
405 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK559930">
|
|
<meta name="ncbi_domain" content="niceng151er17">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK559930/?report=reader">
|
|
<meta name="ncbi_pagename" content="Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Alliance (UK)">
|
|
<meta name="citation_title" content="Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2020/01">
|
|
<meta name="citation_author" content="National Guideline Alliance (UK)">
|
|
<meta name="citation_pmid" content="32730000">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK559930/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Alliance (UK)">
|
|
<meta name="DC.Date" content="2020/01">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK559930/">
|
|
<meta name="og:title" content="Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK559930/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng151er17-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng151er17/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK559930/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8BEA447D7261010000000000B5008D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK559930/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK559930/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK559930/&text=Follow-up%20to%20detect%20recurrence%20after%20treatment%20for%20non-metastatic%20colorectal%20cancer"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK559930/?report=classic">Switch to classic view</a><a href="/books/n/niceng151er17/pdf/">PDF (2.2M)</a><a href="/books/n/niceng151er17/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK559930%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8BEA447D7261010000000000B5008D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng151er17-lrg.png" alt="Cover of Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer" /></a></div><div class="bkr_bib"><h1 id="_NBK559930_"><span itemprop="name">Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer</span></h1><div class="subtitle">Colorectal cancer (update)</div><p><b>Evidence review E1</b></p><p><i>NICE Guideline, No. 151</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Alliance (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2020 Jan</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3657-1</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div></div><div class="bkr_clear"></div></div><div id="ch17.s1"><h2 id="_ch17_s1_">Follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer</h2><p>This evidence review supports <a href="/books/n/niceng151/?report=reader" class="toc-item">recommendation 1.6.1</a>.</p><div id="ch17.s1.1"><h3>Review question</h3><p>What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</p><div id="ch17.s1.1.1"><h4>Introduction</h4><p>People who have potentially curative surgery for colorectal cancer are typically followed-up for a number of years, with the aim of detecting and treating any recurrences at the earliest possible stage. The effectiveness of follow-up to detect treatable recurrences could depend on factors including: the frequency of testing, the type of tests used, the duration of follow-up and the personnel who carry out the tests. Frequent follow-up testing however is resource intensive and could lead to patient anxiety. It also is unclear whether early detection of recurrence consistently leads to better outcomes. This review aimed to determine the optimal follow-up protocol, by comparing the outcomes of patients on different follow-up protocols.</p></div><div id="ch17.s1.1.2"><h4>Summary of the protocol</h4><p>Please see <a class="figpopup" href="/books/NBK559930/table/ch17.tab1/?report=objectonly" target="object" rid-figpopup="figch17tab1" rid-ob="figobch17tab1">Table 1</a> for a summary of the population, intervention, comparison and outcomes (PICO) characteristics of this review.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch17tab1"><a href="/books/NBK559930/table/ch17.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figch17tab1" rid-ob="figobch17tab1"><img class="small-thumb" src="/books/NBK559930/table/ch17.tab1/?report=thumb" src-large="/books/NBK559930/table/ch17.tab1/?report=previmg" alt="Table 1. Summary of the protocol (PICO table)." /></a><div class="icnblk_cntnt"><h4 id="ch17.tab1"><a href="/books/NBK559930/table/ch17.tab1/?report=objectonly" target="object" rid-ob="figobch17tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">Summary of the protocol (PICO table). </p></div></div><p>For further details see the review protocol in <a href="#ch17.appa">appendix A</a>.</p></div><div id="ch17.s1.1.3"><h4>Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>
|
|
<u>2014</u>. Methods specific to this review question are described in the review protocol in <a href="#ch17.appa">appendix A</a>.</p><p>Declarations of interest were recorded according to NICE’s 2014 conflicts of interest policy until 31 March 2018. From 1 April 2018, declarations of interest were recorded according to NICE’s 2018 <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">conflicts of interest policy</a>. Those interests declared until April 2018 were reclassified according to NICE’s 2018 conflicts of interest policy (see Register of Interests).</p></div><div id="ch17.s1.1.4"><h4>Clinical evidence</h4><div id="ch17.s1.1.4.1"><h5>Included studies</h5><p>Seventeen randomised controlled trials (RCTs) reported in 3 publications were included (<a class="bibr" href="#ch17.s1.1.ref2" rid="ch17.s1.1.ref2">CEAwatch 2017</a>; <a class="bibr" href="#ch17.s1.1.ref3" rid="ch17.s1.1.ref3">COLOFOL 2018</a>; <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffrey 2016</a>). Fifteen of the RCTs were reported in a systematic review (<a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffrey 2016</a>). The meta-analyses of <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffrey 2016</a> were updated with 2 additional RCTs (<a class="bibr" href="#ch17.s1.1.ref3" rid="ch17.s1.1.ref3">COLOFOL 2018</a> and <a class="bibr" href="#ch17.s1.1.ref2" rid="ch17.s1.1.ref2">CEAwatch 2017</a>).</p><p>The included studies are summarised in <a class="figpopup" href="/books/NBK559930/table/ch17.tab2/?report=objectonly" target="object" rid-figpopup="figch17tab2" rid-ob="figobch17tab2">Table 2</a>. The follow-up protocols compared in the trials are summarised in <a class="figpopup" href="/books/NBK559930/figure/ch17.fig1/?report=objectonly" target="object" rid-figpopup="figch17fig1" rid-ob="figobch17fig1">Figure 1</a>.</p><p>Nine RCTs compared more follow-up visits or tests to fewer visits or tests (<a class="bibr" href="#ch17.s1.1.ref2" rid="ch17.s1.1.ref2">CEAwatch 2017</a>; <a class="bibr" href="#ch17.s1.1.ref3" rid="ch17.s1.1.ref3">COLOFOL 2018</a>; <a class="bibr" href="#ch17.s1.1.ref7" rid="ch17.s1.1.ref7">Kjeldsen 1997</a>; <a class="bibr" href="#ch17.s1.1.ref8" rid="ch17.s1.1.ref8">Mäkelä 1995</a>; <a class="bibr" href="#ch17.s1.1.ref10" rid="ch17.s1.1.ref10">Pietra 1998</a>; <a class="bibr" href="#ch17.s1.1.ref11" rid="ch17.s1.1.ref11">Rodríguez-Moranta 2006</a>; <a class="bibr" href="#ch17.s1.1.ref13" rid="ch17.s1.1.ref13">Secco 2002</a>; <a class="bibr" href="#ch17.s1.1.ref16" rid="ch17.s1.1.ref16">Treasure 2014</a>; <a class="bibr" href="#ch17.s1.1.ref17" rid="ch17.s1.1.ref17">Wang 2009</a>). Four RCTs compared formal follow-up to minimal or no follow-up up (<a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a>; <a class="bibr" href="#ch17.s1.1.ref9" rid="ch17.s1.1.ref9">Ohlsson 1995</a>; <a class="bibr" href="#ch17.s1.1.ref12" rid="ch17.s1.1.ref12">Schoemaker 1998</a>; <a class="bibr" href="#ch17.s1.1.ref13" rid="ch17.s1.1.ref13">Secco 2002</a>). Five RCTs compared more liver imaging to less liver imaging (<a class="bibr" href="#ch17.s1.1.ref2" rid="ch17.s1.1.ref2">CEAwatch 2017</a>; <a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a>; <a class="bibr" href="#ch17.s1.1.ref5" rid="ch17.s1.1.ref5">GILDA 1998</a>; <a class="bibr" href="#ch17.s1.1.ref11" rid="ch17.s1.1.ref11">Rodríguez-Moranta 2006</a>; <a class="bibr" href="#ch17.s1.1.ref12" rid="ch17.s1.1.ref12">Schoemaker 1998</a>). Four RCTs compared carcinoembryonic antigen (CEA) tests to no CEA tests (<a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a>; <a class="bibr" href="#ch17.s1.1.ref7" rid="ch17.s1.1.ref7">Kjeldsen 1997</a>; <a class="bibr" href="#ch17.s1.1.ref9" rid="ch17.s1.1.ref9">Ohlsson 1995</a>; <a class="bibr" href="#ch17.s1.1.ref16" rid="ch17.s1.1.ref16">Treasure 2014</a>). Three RCTs compared surgeon-led to GP (<a class="bibr" href="#ch17.s1.1.ref1" rid="ch17.s1.1.ref1">Augestad 2013</a>; <a class="bibr" href="#ch17.s1.1.ref18" rid="ch17.s1.1.ref18">Wattchow 2006</a>) or nurse-led follow-up (<a class="bibr" href="#ch17.s1.1.ref15" rid="ch17.s1.1.ref15">Strand 2011</a>).</p><p>See the literature search strategy in <a href="#ch17.appb">appendix B</a> and study selection flow chart in <a href="#ch17.appc">appendix C</a>.</p></div><div id="ch17.s1.1.4.2"><h5>Excluded studies</h5><p>Studies not included in this review with reasons for their exclusions are provided in <a href="#ch17.appk">appendix K</a>.</p></div></div><div id="ch17.s1.1.5"><h4>Summary of clinical studies included in the evidence review</h4><p>Summaries of the studies that were included in this review are presented in <a class="figpopup" href="/books/NBK559930/table/ch17.tab2/?report=objectonly" target="object" rid-figpopup="figch17tab2" rid-ob="figobch17tab2">Table 2</a>. Summaries of the follow-up protocols compared in the trials are presented in <a class="figpopup" href="/books/NBK559930/figure/ch17.fig1/?report=objectonly" target="object" rid-figpopup="figch17fig1" rid-ob="figobch17fig1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch17tab2"><a href="/books/NBK559930/table/ch17.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figch17tab2" rid-ob="figobch17tab2"><img class="small-thumb" src="/books/NBK559930/table/ch17.tab2/?report=thumb" src-large="/books/NBK559930/table/ch17.tab2/?report=previmg" alt="Table 2. Summary of included studies." /></a><div class="icnblk_cntnt"><h4 id="ch17.tab2"><a href="/books/NBK559930/table/ch17.tab2/?report=objectonly" target="object" rid-ob="figobch17tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of included studies. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figch17fig1" co-legend-rid="figlgndch17fig1"><a href="/books/NBK559930/figure/ch17.fig1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="figch17fig1" rid-ob="figobch17fig1"><img class="small-thumb" src="/books/NBK559930/bin/ch17f1.gif" src-large="/books/NBK559930/bin/ch17f1.jpg" alt="Figure 1. Summary of follow-up protocols compared in trials." /></a><div class="icnblk_cntnt" id="figlgndch17fig1"><h4 id="ch17.fig1"><a href="/books/NBK559930/figure/ch17.fig1/?report=objectonly" target="object" rid-ob="figobch17fig1">Figure 1</a></h4><p class="float-caption no_bottom_margin">Summary of follow-up protocols compared in trials. CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CT: computed tomography; FBC: full blood count; FOB: faecal occult blood; PET: positron emission tomography; US: ultrasound </p></div></div><p>See the full evidence tables in <a href="#ch17.appd">appendix D</a> and the forest plots in <a href="#ch17.appe">appendix E</a>.</p></div><div id="ch17.s1.1.6"><h4>Quality assessment of clinical outcomes included in the evidence review</h4><p>See the clinical evidence profiles in <a href="#ch17.appf">appendix F</a>.</p></div><div id="ch17.s1.1.7"><h4>Economic evidence</h4><div id="ch17.s1.1.7.1"><h5>Included studies</h5><p>A systematic review of the economic literature was conducted but no economic studies were identified which were applicable to this review question.</p></div><div id="ch17.s1.1.7.2"><h5>Excluded studies</h5><p>A global search of economic evidence was undertaken for all review questions in this guideline. See Supplement 2 for further information.</p></div></div><div id="ch17.s1.1.8"><h4>Economic model</h4><p>No economic modelling was undertaken for this review because the committee agreed that other topics were higher priorities for economic evaluation.</p></div><div id="ch17.s1.1.9"><h4>Evidence statements</h4><div id="ch17.s1.1.9.1"><h5>Clinical evidence statements</h5><div id="ch17.s1.1.9.1.1"><h5>Comparison 1: More intensive follow-up versus less intensive follow-up</h5><div id="ch17.s1.1.9.1.1.1"><h5>Critical outcomes</h5><div id="ch17.s1.1.9.1.1.1.1"><h5>Overall survival</h5><ul id="ch17.l25"><li id="ch17.lt80" class="half_rhythm"><div>High quality evidence from 14 RCTs including 10532 participants with colorectal cancer (with follow-up ranging from 24 to 66 months) indicated a clinically important improvement in overall survival with a more intensive follow-up schedule compared to less intensive follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.1.1.2"><h5>Colorectal cancer-specific survival</h5><ul id="ch17.l26"><li id="ch17.lt81" class="half_rhythm"><div>Moderate quality evidence from 10 RCTs including 9775 participants with colorectal cancer (with follow-up ranging from 24 to 66 months) indicated no clinically important difference in colorectal cancer-specific survival with a more intensive follow-up schedule compared to less intensive follow-up.</div></li></ul></div></div><div id="ch17.s1.1.9.1.1.2"><h5>Important outcomes</h5><div id="ch17.s1.1.9.1.1.2.1"><h5>Relapse-free survival</h5><ul id="ch17.l27"><li id="ch17.lt82" class="half_rhythm"><div>Moderate quality evidence from 14 RCTs including 8746 participants with colorectal cancer (with follow-up ranging from 24 to 66 months) indicated no clinically important difference in relapse-free survival with a more intensive follow-up schedule compared to less intensive follow-up.</div></li></ul></div></div><div id="ch17.s1.1.9.1.1.3"><h5>Local recurrence</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.1.4"><h5>Distant metastasis</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.1.5"><h5>Metachronous colorectal cancer</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.1.6"><h5>Resectability of recurrent local or metastatic disease</h5><ul id="ch17.l28"><li id="ch17.lt83" class="half_rhythm"><div>High quality evidence from 13 RCTs including 5157 participants with colorectal cancer (with follow-up ranging from 24 to 66 months) indicated resectable recurrences were more likely with a more intensive follow-up schedule compared to less intensive follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.1.7"><h5>Overall quality of life</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.1.8"><h5>Procedure-related morbidity</h5><ul id="ch17.l29"><li id="ch17.lt84" class="half_rhythm"><div>Low quality evidence from one RCT including 1561 follow-up colonoscopies for colorectal cancer showed no clinically important difference in the rates of colonoscopy complications between more versus less intensive follow-up.</div></li></ul></div></div><div id="ch17.s1.1.9.1.2"><h5>Comparison 2: More visits or tests versus fewer visits or tests</h5><div id="ch17.s1.1.9.1.2.1"><h5>Critical outcomes</h5><div id="ch17.s1.1.9.1.2.1.1"><h5>Overall survival</h5><ul id="ch17.l30"><li id="ch17.lt85" class="half_rhythm"><div>High quality evidence from 8 RCTs including 7436 participants with colorectal cancer (with follow-up ranging from 41 to 64 months) indicated a clinically important improvement in overall survival with more follow-up visits or tests compared to fewer visits or tests.</div></li></ul></div><div id="ch17.s1.1.9.1.2.1.2"><h5>Colorectal cancer-specific survival</h5><ul id="ch17.l31"><li id="ch17.lt86" class="half_rhythm"><div>Moderate quality evidence from 8 RCTs including 7114 participants with colorectal cancer (with follow-up ranging from 41 to 64 months) indicated there may be a clinically important improvement in colorectal cancer-specific survival with more follow-up visits or tests compared to fewer visits or tests, but there was uncertainty in the estimate.</div></li></ul></div></div><div id="ch17.s1.1.9.1.2.2"><h5>Important outcomes</h5><div id="ch17.s1.1.9.1.2.2.1"><h5>Relapse-free survival</h5><ul id="ch17.l32"><li id="ch17.lt87" class="half_rhythm"><div>Moderate quality evidence from 9 RCTs including 6397 participants with colorectal cancer (with follow-up ranging from 41 to 64 months) indicated no clinically important difference relapse-free survival with more follow-up visits or tests compared to fewer visits or tests.</div></li></ul></div><div id="ch17.s1.1.9.1.2.2.2"><h5>Local recurrence</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.2.2.3"><h5>Distant metastasis</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.2.2.4"><h5>Metachronous colorectal cancer</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.2.2.5"><h5>Resectability of recurrent local or metastatic disease</h5><ul id="ch17.l33"><li id="ch17.lt88" class="half_rhythm"><div>Moderate quality evidence from 7 RCTs including 2041 participants with colorectal cancer (with follow-up ranging from 41 to 64 months) indicated resectable recurrences were more likely with more follow-up visits or tests compared to fewer visits or tests.</div></li></ul></div><div id="ch17.s1.1.9.1.2.2.6"><h5>Overall quality of life</h5><ul id="ch17.l34"><li id="ch17.lt89" class="half_rhythm"><div>Low quality evidence from 1 RCT including 350 participants with colorectal cancer indicated a small increase in quality of life, as measured by the Nottingham Health Profile, associated with more frequent follow-up visits compared with less frequent follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.2.2.7"><h5>Procedure-related morbidity</h5><ul id="ch17.l35"><li id="ch17.lt90" class="half_rhythm"><div>Low quality evidence from 1 RCT including 1561 follow-up colonoscopies for colorectal cancer showed no clinically important difference in the rates of colonoscopy complications between more versus less intensive follow-up.</div></li></ul></div></div></div><div id="ch17.s1.1.9.1.3"><h5>Comparison 3: Visits or tests versus minimal or no follow-up</h5><div id="ch17.s1.1.9.1.3.1"><h5>Critical outcomes</h5><div id="ch17.s1.1.9.1.3.1.1"><h5>Overall survival</h5><ul id="ch17.l36"><li id="ch17.lt91" class="half_rhythm"><div>High quality evidence from 3 RCTs including 1634 participants with colorectal cancer (with follow-up ranging from 41 to 66 months) indicated no clinically important difference in overall survival with follow-up visits or tests compared to minimal or no follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.3.1.2"><h5>Colorectal cancer-specific survival</h5><ul id="ch17.l37"><li id="ch17.lt92" class="half_rhythm"><div>High quality evidence from 2 RCTs including 1309 participants with colorectal cancer (with follow-up ranging from 41 to 66 months) indicated no clinically important difference in colorectal cancer-specific survival with follow-up visits or tests compared to minimal or no follow-up.</div></li></ul></div></div><div id="ch17.s1.1.9.1.3.2"><h5>Important outcomes</h5><div id="ch17.s1.1.9.1.3.2.1"><h5>Relapse-free survival</h5><ul id="ch17.l38"><li id="ch17.lt93" class="half_rhythm"><div>Low quality evidence from 4 RCTs including 1971 participants with colorectal cancer (with follow-up ranging from 41 to 66 months) indicated no clinically important difference in relapse-free survival with follow-up visits or tests compared to minimal or no follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.3.2.2"><h5>Local recurrence</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.3.2.3"><h5>Distant metastasis</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.3.2.4"><h5>Metachronous colorectal cancer</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.3.2.5"><h5>Resectability of recurrent local or metastatic disease</h5><ul id="ch17.l39"><li id="ch17.lt94" class="half_rhythm"><div>Moderate quality evidence from 4 RCTS including 1971 participants with colorectal cancer (with follow-up ranging from 41 to 66 months) indicated resectable recurrences were more likely with follow-up visits or tests compared to minimal or no follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.3.2.6"><h5>Overall quality of life</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.3.2.7"><h5>Procedure-related morbidity</h5><p>No evidence was identified to inform this outcome.</p></div></div></div><div id="ch17.s1.1.9.1.4"><h5>Comparison 4: More liver imaging versus less liver imaging</h5><div id="ch17.s1.1.9.1.4.1"><h5>Critical outcomes</h5><div id="ch17.s1.1.9.1.4.1.1"><h5>Overall survival</h5><ul id="ch17.l40"><li id="ch17.lt95" class="half_rhythm"><div>Moderate quality evidence from 4 RCTs including 5036 participants with colorectal cancer (with follow-up ranging from 48 to 60 months) indicated no clinically important difference in overall survival with more liver imaging during follow-up compared to less liver-imaging.</div></li></ul></div><div id="ch17.s1.1.9.1.4.1.2"><h5>Colorectal cancer-specific survival</h5><ul id="ch17.l41"><li id="ch17.lt96" class="half_rhythm"><div>Moderate quality evidence from 3 RCTs including 4724 participants with colorectal cancer (with follow-up ranging from 48 to 60 months) indicated no clinically important difference in colorectal cancer-specific survival with more liver imaging during follow-up compared to less liver-imaging.</div></li></ul></div></div><div id="ch17.s1.1.9.1.4.2"><h5>Important outcomes</h5><div id="ch17.s1.1.9.1.4.2.1"><h5>Relapse-free survival</h5><ul id="ch17.l42"><li id="ch17.lt97" class="half_rhythm"><div>Moderate quality evidence from 3 RCTs including 3026 participants with colorectal cancer (with follow-up ranging from 48 to 60 months) indicated no clinically important difference in relapse-free survival with more liver imaging during follow-up compared to less liver imaging.</div></li></ul></div><div id="ch17.s1.1.9.1.4.2.2"><h5>Local recurrence</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.4.2.3"><h5>Distant metastasis</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.4.2.4"><h5>Metachronous colorectal cancer</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.4.2.5"><h5>Resectability of recurrent local or metastatic disease</h5><ul id="ch17.l43"><li id="ch17.lt98" class="half_rhythm"><div>Low quality evidence from 4 RCTs including 3026 participants with colorectal cancer (with follow-up ranging from 48 to 60 months) indicated resectable recurrences were more likely with more liver imaging during follow-up compared to less liver-imaging.</div></li></ul></div><div id="ch17.s1.1.9.1.4.2.6"><h5>Overall quality of life</h5><ul id="ch17.l44"><li id="ch17.lt99" class="half_rhythm"><div>Moderate quality evidence from 1 RCT including 1228 participants with colorectal cancer followed up for 60 months indicated no clinically important differences among the three main quality of life scales (SF-12 mental component, SF-12 physical component, and PGWB Index) between follow-up with more liver imaging compared to less liver-imaging.</div></li></ul></div><div id="ch17.s1.1.9.1.4.2.7"><h5>Procedure-related morbidity</h5><p>No evidence was identified to inform this outcome.</p></div></div></div><div id="ch17.s1.1.9.1.5"><h5>Comparison 5: CEA tests versus no CEA tests</h5><div id="ch17.s1.1.9.1.5.1"><h5>Critical outcomes</h5><div id="ch17.s1.1.9.1.5.1.1"><h5>Overall survival</h5><ul id="ch17.l45"><li id="ch17.lt100" class="half_rhythm"><div>Moderate quality evidence from 3 RCTs including 920 participants with colorectal cancer (with 66 months follow-up) indicated no clinically important difference in overall survival with follow-up involving CEA tests compared to follow-up without CEA tests.</div></li></ul></div><div id="ch17.s1.1.9.1.5.1.2"><h5>Colorectal cancer-specific survival</h5><ul id="ch17.l46"><li id="ch17.lt101" class="half_rhythm"><div>Moderate quality evidence from 2 RCTs including 704 participants with colorectal cancer (with 66 months follow-up) indicated no clinically important difference in colorectal cancer-specific survival with follow-up involving CEA tests compared to follow-up without CEA tests.</div></li></ul></div></div><div id="ch17.s1.1.9.1.5.2"><h5>Important outcomes</h5><div id="ch17.s1.1.9.1.5.2.1"><h5>Relapse-free survival</h5><ul id="ch17.l47"><li id="ch17.lt102" class="half_rhythm"><div>Moderate quality evidence from 3 RCTs including 920 participants with colorectal cancer (with 66 months follow-up) indicated no clinically important difference in relapse-free survival with follow-up involving CEA tests compared to follow-up without CEA tests.</div></li></ul></div><div id="ch17.s1.1.9.1.5.2.2"><h5>Local recurrence</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.5.2.3"><h5>Distant metastasis</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.5.2.4"><h5>Metachronous colorectal cancer</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.5.2.5"><h5>Resectability of recurrent local or metastatic disease</h5><ul id="ch17.l48"><li id="ch17.lt103" class="half_rhythm"><div>Very low quality evidence from 4 RCTs including 2120 participants with colorectal cancer (with follow-up ranging from 41 to 66 months) indicated resectable recurrence was more likely with follow-up involving CEA tests than with follow-up without CEA tests.</div></li></ul></div><div id="ch17.s1.1.9.1.5.2.6"><h5>Overall quality of life</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.5.2.7"><h5>Procedure-related morbidity</h5><p>No evidence was identified to inform this outcome.</p></div></div></div><div id="ch17.s1.1.9.1.6"><h5>Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up</h5><div id="ch17.s1.1.9.1.6.1"><h5>Critical outcomes</h5><div id="ch17.s1.1.9.1.6.1.1"><h5>Overall survival</h5><ul id="ch17.l49"><li id="ch17.lt104" class="half_rhythm"><div>Moderate quality evidence from 2 RCTs including 220 participants with colorectal cancer (with follow-up ranging from 24 to 60 months) indicated no clinically important difference in overall survival with nurse or GP led follow-up compared to surgeon led follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.6.1.2"><h5>Colorectal cancer-specific survival</h5><ul id="ch17.l50"><li id="ch17.lt105" class="half_rhythm"><div>Moderate quality evidence from 1 RCT including 110 participants with colorectal cancer (with 24 months follow-up) indicated no clinically important difference in overall survival with GP led follow-up compared to surgeon led follow-up.</div></li></ul></div></div><div id="ch17.s1.1.9.1.6.2"><h5>Important outcomes</h5><div id="ch17.s1.1.9.1.6.2.1"><h5>Relapse-free survival</h5><ul id="ch17.l51"><li id="ch17.lt106" class="half_rhythm"><div>Moderate quality evidence from 2 RCTs including 220 participants with colorectal cancer (with follow-up ranging from 24 to 60 months) indicated no clinically important difference in relapse-free survival with nurse or GP led follow-up compared to surgeon led follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.6.2.2"><h5>Local recurrence</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.6.2.3"><h5>Distant metastasis</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.6.2.4"><h5>Metachronous colorectal cancer</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch17.s1.1.9.1.6.2.5"><h5>Resectability of recurrent local or metastatic disease</h5><ul id="ch17.l52"><li id="ch17.lt107" class="half_rhythm"><div>Moderate quality evidence from 1 RCT including 110 participants with colorectal cancer (with 24 months follow-up) indicated no clinically important difference in the likelihood of resectable recurrences with GP led follow-up compared to surgeon led follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.6.2.6"><h5>Overall quality of life</h5><ul id="ch17.l53"><li id="ch17.lt108" class="half_rhythm"><div>Moderate quality evidence from 1 RCT including 110 participants with colorectal cancer (with 24 months follow-up) indicated no significant effect on quality of life main outcome measures with GP led follow-up compared to surgeon led follow-up. For EORTC QLQ-C30, significant effects in favour of GP led follow-up were reported for role functioning, emotional functioning, and pain. A second RCT including 203 participants found no important differences between health-related quality of life in primary versus secondary care follow-up.</div></li></ul></div><div id="ch17.s1.1.9.1.6.2.7"><h5>Procedure-related morbidity</h5><p>No evidence was identified to inform this outcome.</p></div></div></div></div><div id="ch17.s1.1.9.2"><h5>Economic evidence statements</h5><p>No economic evidence was identified which was applicable to this review question.</p></div></div><div id="ch17.s1.1.10"><h4>The committee’s discussion of the evidence</h4><div id="ch17.s1.1.10.1"><h5>Interpreting the evidence</h5><div id="ch17.s1.1.10.1.1"><h5>The outcomes that matter most</h5><p>The critical outcomes for decision making were overall and cancer-specific survival because the aim of follow-up for detection of recurrence is to prolong survival by early treatment of any recurrences found. Recurrence (both local and distant) and metachronous primary disease were important outcomes and any follow-up test needs be able to detect these. Resectability of recurrent disease was also an important outcome, because recurrence has to be detected at an early and treatable stage if follow-up is to be worthwhile. Finally quality of life and procedure related morbidity were important outcomes because some patients experience anxiety related to follow-up testing and the tests themselves can have adverse effects.</p></div><div id="ch17.s1.1.10.1.2"><h5>The quality of the evidence</h5><p>Evidence was available for the comparison of intensity of follow-up, content of the follow-up and setting/personnel in charge of the follow-up. No evidence was identified for duration of follow-up. Evidence was available for critical outcomes on all comparisons. No evidence was identified for the outcomes local recurrence, distant metastases and metachronous colorectal cancer. Evidence about procedure related morbidity and quality of life was limited to a single trial in each case.</p><p>The quality of the evidence was assessed using GRADE, and varied from low to high quality. Evidence was downgraded for lack of blinding, inadequate allocation concealment, for inconsistency and for imprecision.</p></div><div id="ch17.s1.1.10.1.3"><h5>Benefits and harms</h5><p>The recommendation to offer follow-up for the first 3 years that includes serum CEA and CT (of the chest, abdomen and pelvis) for people who have had potentially curative surgical treatment for non-metastatic colorectal cancer is based on evidence that recurrent disease was more likely to be resectable when patients received regular follow-up tests than with minimal or no follow-up. The evidence also showed recurrent disease was more likely to be resectable when follow-up tests included CEA and liver imaging. The committee agreed that the ability to completely resect recurrent disease would lead to improved survival in the longer term.</p><p>Evidence about test-related morbidity was limited to a single randomised trial, which did not find an increased risk with more intense follow-up. The committee agreed that the evidence did not indicate the optimal frequency of CEA or CT testing and so they did not recommend how often these tests should be done during the first 3 years of follow-up. Following the 2011 guideline the committee considered standard practice would be a minimum of two CTs of the chest, abdomen, and pelvis in the first 3 years and with CEA tests at least every 6 months in the first 3 years. The committee thought that recommending a more intense follow-up protocol than that recommended in the 2011 guideline was not justified due to the costs, patient anxiety, potential test related-morbidity and consequences of false positive tests.</p></div></div><div id="ch17.s1.1.10.2"><h5>Cost effectiveness and resource use</h5><p>A systematic review of the economic literature was conducted but no relevant studies were identified which were applicable to this review question.</p><p>The recommendations represent current practice. There will therefore be no associated resource impact.</p></div><div id="ch17.s1.1.10.3"><h5>Other factors the committee took into account</h5><p>The use of follow-up colonoscopy was not covered in the recommendations as this has a different purpose to CEA or CT testing and is covered by guidance from the British Society of Gastroenterology (BSG) and the Association of Coloproctology for Great Britain and Ireland (ACPGBI). Where CEA testing and CT scanning is used to detect recurrence, colonoscopy is used to prevent and detect further tumours.</p></div></div><div id="ch17.rl.r1"><h4>References</h4><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref1"><p id="p-232">
|
|
<strong>Augestad 2013</strong>
|
|
</p>Augestad
|
|
K, Norum
|
|
J, Dehof
|
|
S, et al. (2013) Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open
|
|
3(4): e002391 [<a href="/pmc/articles/PMC3641467/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641467</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23564936" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23564936</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref2"><p id="p-233">
|
|
<strong>CEAwatch 2017</strong>
|
|
</p>Verberne
|
|
C, Zhan
|
|
Z, van den Heuvel
|
|
E, et al. (2017) Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery
|
|
104(8): 1069–1077 [<a href="https://pubmed.ncbi.nlm.nih.gov/28376235" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28376235</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref3"><p id="p-234">
|
|
<strong>COLOFOL 2018</strong>
|
|
</p>Wille-Jørgensen
|
|
P, Syk
|
|
I, Smedh
|
|
K, et al. (2018) COLOFOL Study Group. Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with Stage II or III colorectal cancer: The COLOFOL randomized clinical trial. Journal of the American Medical Association
|
|
319(20): 2095–2103 [<a href="/pmc/articles/PMC6583244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6583244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29800179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29800179</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref4"><p id="p-235">
|
|
<strong>FACS 2014</strong>
|
|
</p>Primrose
|
|
J, Perera
|
|
R, Gray
|
|
A, et al. (2014) Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Journal of the American Medical Association
|
|
311(3): 263–270 [<a href="https://pubmed.ncbi.nlm.nih.gov/24430319" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24430319</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref5"><p id="p-236">
|
|
<strong>GILDA 1998</strong>
|
|
</p>Grossmann
|
|
E, Johnson
|
|
F, Virgo
|
|
K, et al. (2004) Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Surgical Oncology
|
|
13(2-3): 119–124 [<a href="https://pubmed.ncbi.nlm.nih.gov/15572094" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15572094</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref6"><p id="p-237">
|
|
<strong>Jeffery 2016</strong>
|
|
</p>Jeffery
|
|
M, Hickey
|
|
B, Hider
|
|
P, et al. (2016) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database of Systematic Reviews issue 11: CD002200 [<a href="/pmc/articles/PMC6464536/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6464536</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27884041" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27884041</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref7"><p id="p-238">
|
|
<strong>Kjeldsen 1997</strong>
|
|
</p>Kjeldsen
|
|
B, Kronborg
|
|
O, Fenger
|
|
C, et al. (1997) A prospective randomised study of follow-up after radical surgery for colorectal cancer. British Journal of Surgery
|
|
84(5): 666–669 [<a href="https://pubmed.ncbi.nlm.nih.gov/9171758" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9171758</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref8"><p id="p-239">
|
|
<strong>Mäkelä 1995</strong>
|
|
</p>Mäkelä
|
|
J, Laitinen
|
|
S and Kairaluoma
|
|
M (1995) Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery
|
|
130(10): 1062–1067 [<a href="https://pubmed.ncbi.nlm.nih.gov/7575117" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7575117</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref9"><p id="p-240">
|
|
<strong>Ohlsson 1995</strong>
|
|
</p>Ohlsson
|
|
B, Breland
|
|
U, Ekberg
|
|
H, et al. (1995) Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Diseases of the Colon and Rectum
|
|
38(6):619–626. [<a href="https://pubmed.ncbi.nlm.nih.gov/7774474" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7774474</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref10"><p id="p-241">
|
|
<strong>Pietra 1998</strong>
|
|
</p>Pietra
|
|
N, Sarli
|
|
L, Costi
|
|
R, et al. (1998) Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum
|
|
41(9): 1127–1133 [<a href="https://pubmed.ncbi.nlm.nih.gov/9749496" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9749496</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref11"><p id="p-242">
|
|
<strong>Rodríguez-Moranta 2006</strong>
|
|
</p>Rodríguez-Moranta
|
|
F, Saló
|
|
J, Arcusa
|
|
A, et al. (2006) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology
|
|
24(3): 386–393 [<a href="https://pubmed.ncbi.nlm.nih.gov/16365182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16365182</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref12"><p id="p-243">
|
|
<strong>Schoemaker 1998</strong>
|
|
</p>Schoemaker
|
|
D, Black
|
|
R, Giles
|
|
L, et al. (1998) Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gasteroenterology
|
|
114(1): 7–14 [<a href="https://pubmed.ncbi.nlm.nih.gov/9428212" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9428212</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref13"><p id="p-244">
|
|
<strong>Secco 2002</strong>
|
|
</p>Secco
|
|
G, Fardelli
|
|
R, Gianquinto
|
|
D, et al. (2002) Efficacy and cost of risk adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology
|
|
28(4): 418–423 [<a href="https://pubmed.ncbi.nlm.nih.gov/12099653" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12099653</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref14"><p id="p-245">
|
|
<strong>Sobhani 2008</strong>
|
|
</p>Sobhani
|
|
I, Tiret
|
|
E, Labtahi
|
|
R, et al. (2008) Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. British Journal of Cancer
|
|
98(5): 875–880 [<a href="/pmc/articles/PMC2266857/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2266857</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18301402" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18301402</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref15"><p id="p-246">
|
|
<strong>Strand 2011</strong>
|
|
</p>Strand
|
|
E, Nygren
|
|
I, Bergkvist
|
|
L, et al. (2011) Nurse or surgeon follow-up after rectal cancer: a randomized trial. Colorectal Disease
|
|
13(9): 999–1003 [<a href="https://pubmed.ncbi.nlm.nih.gov/20478003" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20478003</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref16"><p id="p-247">
|
|
<strong>Treasure 2014</strong>
|
|
</p>Treasure
|
|
T, Monson
|
|
K, Fiorentino
|
|
F
|
|
et al. (2014) The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ Open
|
|
4(5): e004385 [<a href="/pmc/articles/PMC4025449/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4025449</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24823671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24823671</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref17"><p id="p-248">
|
|
<strong>Wang 2009</strong>
|
|
</p>Wang
|
|
T, Cui
|
|
Y, Huang
|
|
W, et al. (2009) The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy
|
|
69(3 Pt 2): 609–615 [<a href="https://pubmed.ncbi.nlm.nih.gov/19136105" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19136105</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch17.s1.1.ref18"><p id="p-249">
|
|
<strong>Wattchow 2006</strong>
|
|
</p>Wattchow
|
|
D, Weller
|
|
D, Esterman
|
|
A, et al. (2006) General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. British Journal of Cancer
|
|
94(8): 1116–1121 [<a href="/pmc/articles/PMC2361245/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2361245</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16622437" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16622437</span></a>]</div></p></li></ul></div></div></div><div id="appendixesappgroup17"><h2 id="_appendixesappgroup17_">Appendices</h2><div id="ch17.appa"><h3>Appendix A. Review protocol</h3><div id="ch17.appa.s1"><h4>Review protocol for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p id="ch17.appa.tab1"><a href="/books/NBK559930/table/ch17.appa.tab1/?report=objectonly" target="object" rid-ob="figobch17appatab1" class="figpopup">Table 3. Review protocol for the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer</a></p></div></div><div id="ch17.appb"><h3>Appendix B. Literature search strategies</h3><div id="ch17.appb.s1"><h4>Literature search strategies for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><div id="ch17.appb.s1.1"><h5>Database: Embase/Medline</h5><p>Last searched on: 12/02/2019</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch17appbtab1"><a href="/books/NBK559930/table/ch17.appb.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figch17appbtab1" rid-ob="figobch17appbtab1"><img class="small-thumb" src="/books/NBK559930/table/ch17.appb.tab1/?report=thumb" src-large="/books/NBK559930/table/ch17.appb.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ch17.appb.tab1"><a href="/books/NBK559930/table/ch17.appb.tab1/?report=objectonly" target="object" rid-ob="figobch17appbtab1">Table</a></h4></div></div></div><div id="ch17.appb.s1.2"><h5>Database: Cochrane Library</h5><p>Last searched on: 12/02/2019</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch17appbtab2"><a href="/books/NBK559930/table/ch17.appb.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figch17appbtab2" rid-ob="figobch17appbtab2"><img class="small-thumb" src="/books/NBK559930/table/ch17.appb.tab2/?report=thumb" src-large="/books/NBK559930/table/ch17.appb.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ch17.appb.tab2"><a href="/books/NBK559930/table/ch17.appb.tab2/?report=objectonly" target="object" rid-ob="figobch17appbtab2">Table</a></h4></div></div></div></div></div><div id="ch17.appc"><h3>Appendix C. Clinical evidence study selection</h3><div id="ch17.appc.s1"><h4>Clinical study selection for: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p id="ch17.appc.fig1"><a href="/books/NBK559930/figure/ch17.appc.fig1/?report=objectonly" target="object" rid-ob="figobch17appcfig1" class="figpopup">Figure 2. Study selection flow chart</a></p></div></div><div id="ch17.appd"><h3>Appendix D. Clinical evidence tables</h3><div id="ch17.appd.s1"><h4>Clinical evidence tables for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p id="ch17.appd.et1"><a href="/books/NBK559930/bin/ch17-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 4. Clinical evidence tables</a><span class="small"> (PDF, 351K)</span></p></div></div><div id="ch17.appe"><h3>Appendix E. Forest plots</h3><div id="ch17.appe.s1"><h4>Forest plots for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p id="ch17.appe.fig1"><a href="/books/NBK559930/figure/ch17.appe.fig1/?report=objectonly" target="object" rid-ob="figobch17appefig1" class="figpopup">Figure 3. Comparison 1: More intensive versus less intensive follow-up – Overall survival (follow-up 24 to 66 months)</a></p><p id="ch17.appe.fig2"><a href="/books/NBK559930/figure/ch17.appe.fig2/?report=objectonly" target="object" rid-ob="figobch17appefig2" class="figpopup">Figure 4. Comparison 1: More intensive versus less intensive follow-up – Colorectal 7 cancer-specific survival (follow-up 24 to 66 months)</a></p><p id="ch17.appe.fig3"><a href="/books/NBK559930/figure/ch17.appe.fig3/?report=objectonly" target="object" rid-ob="figobch17appefig3" class="figpopup">Figure 5. Comparison 1: More intensive versus less intensive follow-up – Relapse-free survival (follow-up 24 to 66 months)</a></p><p id="ch17.appe.fig4"><a href="/books/NBK559930/figure/ch17.appe.fig4/?report=objectonly" target="object" rid-ob="figobch17appefig4" class="figpopup">Figure 6. Comparison 1: More intensive versus less intensive follow-up – Resectable recurrent disease (follow-up 24 to 66 months)</a></p><p id="ch17.appe.fig5"><a href="/books/NBK559930/figure/ch17.appe.fig5/?report=objectonly" target="object" rid-ob="figobch17appefig5" class="figpopup">Figure 7. Comparison 1: More intensive versus less intensive follow-up – Procedure-related morbidity (follow-up 64 months)</a></p><p id="ch17.appe.fig6"><a href="/books/NBK559930/figure/ch17.appe.fig6/?report=objectonly" target="object" rid-ob="figobch17appefig6" class="figpopup">Figure 8. Comparison 2: More visits or tests versus fewer visits or tests – Overall survival (follow-up 41 to 64 months)</a></p><p id="ch17.appe.fig7"><a href="/books/NBK559930/figure/ch17.appe.fig7/?report=objectonly" target="object" rid-ob="figobch17appefig7" class="figpopup">Figure 9. Comparison 2: More visits or tests versus fewer visits or tests – Colorectal cancer-specific survival (follow-up 41 to 64 months)</a></p><p id="ch17.appe.fig8"><a href="/books/NBK559930/figure/ch17.appe.fig8/?report=objectonly" target="object" rid-ob="figobch17appefig8" class="figpopup">Figure 10. Comparison 2: More visits or tests versus fewer visits or tests – Relapse-free survival (follow-up 41 to 64 months)</a></p><p id="ch17.appe.fig9"><a href="/books/NBK559930/figure/ch17.appe.fig9/?report=objectonly" target="object" rid-ob="figobch17appefig9" class="figpopup">Figure 11. Comparison 2: More visits or tests versus fewer visits or tests – Resectable recurrent disease (follow-up 41 to 64 months)</a></p><p id="ch17.appe.fig10"><a href="/books/NBK559930/figure/ch17.appe.fig10/?report=objectonly" target="object" rid-ob="figobch17appefig10" class="figpopup">Figure 12. Comparison 2: More visits or tests versus fewer visits or tests – Procedure-related morbidity (follow-up 64 months)</a></p><p id="ch17.appe.fig11"><a href="/books/NBK559930/figure/ch17.appe.fig11/?report=objectonly" target="object" rid-ob="figobch17appefig11" class="figpopup">Figure 13. Comparison 3: Visits or tests versus minimal or no follow-up – Overall survival (follow-up 41 to 66 months)</a></p><p id="ch17.appe.fig12"><a href="/books/NBK559930/figure/ch17.appe.fig12/?report=objectonly" target="object" rid-ob="figobch17appefig12" class="figpopup">Figure 14. Comparison 3: Visits or tests versus minimal or no follow-up – Colorectal cancer-specific survival (follow-up 41 to 66 months)</a></p><p id="ch17.appe.fig13"><a href="/books/NBK559930/figure/ch17.appe.fig13/?report=objectonly" target="object" rid-ob="figobch17appefig13" class="figpopup">Figure 15. Comparison 3: Visits or tests versus minimal or no follow-up – Relapse-free survival (follow-up 41 to 66 months)</a></p><p id="ch17.appe.fig14"><a href="/books/NBK559930/figure/ch17.appe.fig14/?report=objectonly" target="object" rid-ob="figobch17appefig14" class="figpopup">Figure 16. Comparison 3: Visits or tests versus minimal or no follow-up – Resectable recurrent disease (follow-up 41 to 66 months)</a></p><p id="ch17.appe.fig15"><a href="/books/NBK559930/figure/ch17.appe.fig15/?report=objectonly" target="object" rid-ob="figobch17appefig15" class="figpopup">Figure 17. Comparison 4: More liver imaging versus less liver imaging – Overall survival (follow-up 48 to 60 months)</a></p><p id="ch17.appe.fig16"><a href="/books/NBK559930/figure/ch17.appe.fig16/?report=objectonly" target="object" rid-ob="figobch17appefig16" class="figpopup">Figure 18. Comparison 4: More liver imaging versus less liver imaging – Colorectal cancer-specific survival (follow-up 48 to 60 months)</a></p><p id="ch17.appe.fig17"><a href="/books/NBK559930/figure/ch17.appe.fig17/?report=objectonly" target="object" rid-ob="figobch17appefig17" class="figpopup">Figure 19. Comparison 4: More liver imaging versus less liver imaging – Relapse-free survival (follow-up 48 to 60 months)</a></p><p id="ch17.appe.fig18"><a href="/books/NBK559930/figure/ch17.appe.fig18/?report=objectonly" target="object" rid-ob="figobch17appefig18" class="figpopup">Figure 20. Comparison 4: More liver imaging versus less liver imaging – Resectable recurrent disease (follow-up 48 to 60 months)</a></p><p id="ch17.appe.fig19"><a href="/books/NBK559930/figure/ch17.appe.fig19/?report=objectonly" target="object" rid-ob="figobch17appefig19" class="figpopup">Figure 21. Comparison 5: CEA tests versus no CEA tests – Overall survival (follow-up 66 months)</a></p><p id="ch17.appe.fig20"><a href="/books/NBK559930/figure/ch17.appe.fig20/?report=objectonly" target="object" rid-ob="figobch17appefig20" class="figpopup">Figure 22. Comparison 5: CEA tests versus no CEA tests – Colorectal cancer-specific survival (follow-up 66 months)</a></p><p id="ch17.appe.fig21"><a href="/books/NBK559930/figure/ch17.appe.fig21/?report=objectonly" target="object" rid-ob="figobch17appefig21" class="figpopup">Figure 23. Comparison 5: CEA tests versus no CEA tests – Relapse-free survival (follow-up 66 months)</a></p><p id="ch17.appe.fig22"><a href="/books/NBK559930/figure/ch17.appe.fig22/?report=objectonly" target="object" rid-ob="figobch17appefig22" class="figpopup">Figure 24. Comparison 5: CEA tests versus no CEA tests – Resectable recurrent disease (follow-up 41 to 66 months)</a></p><p id="ch17.appe.fig23"><a href="/books/NBK559930/figure/ch17.appe.fig23/?report=objectonly" target="object" rid-ob="figobch17appefig23" class="figpopup">Figure 25. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Overall survival (follow-up 24 to 60 months)</a></p><p id="ch17.appe.fig24"><a href="/books/NBK559930/figure/ch17.appe.fig24/?report=objectonly" target="object" rid-ob="figobch17appefig24" class="figpopup">Figure 26. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Colorectal cancer-specific survival (follow-up 24 months)</a></p><p id="ch17.appe.fig25"><a href="/books/NBK559930/figure/ch17.appe.fig25/?report=objectonly" target="object" rid-ob="figobch17appefig25" class="figpopup">Figure 27. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Relapse-free survival (follow-up 24 to 60 months)</a></p><p id="ch17.appe.fig26"><a href="/books/NBK559930/figure/ch17.appe.fig26/?report=objectonly" target="object" rid-ob="figobch17appefig26" class="figpopup">Figure 28. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Resectable recurrent disease (follow-up 24 months)</a></p></div></div><div id="ch17.appf"><h3>Appendix F. GRADE tables</h3><div id="ch17.appf.s1"><h4>GRADE tables for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p id="ch17.appf.tab1"><a href="/books/NBK559930/table/ch17.appf.tab1/?report=objectonly" target="object" rid-ob="figobch17appftab1" class="figpopup">Table 5. Clinical evidence profile for comparison 1: More intensive versus less intensive follow-up</a></p><p id="ch17.appf.tab2"><a href="/books/NBK559930/table/ch17.appf.tab2/?report=objectonly" target="object" rid-ob="figobch17appftab2" class="figpopup">Table 6. Clinical evidence profile for comparison 2: More visits or tests versus fewer visits or tests</a></p><p id="ch17.appf.tab3"><a href="/books/NBK559930/table/ch17.appf.tab3/?report=objectonly" target="object" rid-ob="figobch17appftab3" class="figpopup">Table 7. Clinical evidence profile for comparison 3: Visits or tests versus minimal or no follow-up</a></p><p id="ch17.appf.tab4"><a href="/books/NBK559930/table/ch17.appf.tab4/?report=objectonly" target="object" rid-ob="figobch17appftab4" class="figpopup">Table 8. Clinical evidence profile for comparison 4: More liver imaging versus less liver imaging</a></p><p id="ch17.appf.tab5"><a href="/books/NBK559930/table/ch17.appf.tab5/?report=objectonly" target="object" rid-ob="figobch17appftab5" class="figpopup">Table 9. Clinical evidence profile for comparison 5: CEA tests versus no CEA tests</a></p><p id="ch17.appf.tab6"><a href="/books/NBK559930/table/ch17.appf.tab6/?report=objectonly" target="object" rid-ob="figobch17appftab6" class="figpopup">Table 10. Clinical evidence profile for comparison 6: Nurse or GP led follow-up versus surgeon led follow-up</a></p></div></div><div id="ch17.appg"><h3>Appendix G. Economic evidence study selection</h3><div id="ch17.appg.s1"><h4>Economic evidence study selection for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p>A global search of economic evidence was undertaken for all review questions in this guideline. See Supplement 2 for further information.</p></div></div><div id="ch17.apph"><h3>Appendix H. Economic evidence tables</h3><div id="ch17.apph.s1"><h4>Economic evidence tables for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p>No economic evidence was identified which was applicable to this review question.</p></div></div><div id="ch17.appi"><h3>Appendix I. Economic evidence profiles</h3><div id="ch17.appi.s1"><h4>Economic evidence profiles for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p>No economic evidence was identified which was applicable to this review question.</p></div></div><div id="ch17.appj"><h3>Appendix J. Economic analysis</h3><div id="ch17.appj.s1"><h4>Economic evidence analysis for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p>No economic analysis was conducted for this review question.</p></div></div><div id="ch17.appk"><h3>Appendix K. Excluded studies</h3><div id="ch17.appk.s1"><h4>Excluded clinical studies for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p id="ch17.appk.tab1"><a href="/books/NBK559930/table/ch17.appk.tab1/?report=objectonly" target="object" rid-ob="figobch17appktab1" class="figpopup">Table 11. Excluded studies and reasons for their exclusion</a></p></div></div><div id="ch17.appl"><h3>Appendix L. Research recommendations</h3><div id="ch17.appl.s1"><h4>Research recommendations for review question: What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</h4><p>No research recommendations were made for this review question.</p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews</p><p>Developed by the National Guideline Alliance part of the Royal College of Obstetricians and Gynaecologists</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div><div class="small"><span class="label">Bookshelf ID: NBK559930</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32730000" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">32730000</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobch17tab1"><div id="ch17.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">Summary of the protocol (PICO table)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.tab1_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ch17.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_ch17.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults who have undergone surgical or endoscopic resection for non-metastatic colorectal cancer (colon cancer or rectal cancer) with curative intent (with or without adjuvant therapy).
|
|
<ul id="ch17.l1"><li id="ch17.lt1" class="half_rhythm"><div>T any</div></li><li id="ch17.lt2" class="half_rhythm"><div>N any</div></li><li id="ch17.lt3" class="half_rhythm"><div>M0</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_ch17.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><td headers="hd_b_ch17.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Follow-up strategy taking into consideration one or more of the following elements:
|
|
<ul id="ch17.l2"><li id="ch17.lt4" class="half_rhythm"><div>Intensity/frequency of follow-up</div></li><li id="ch17.lt5" class="half_rhythm"><div>Duration of follow-up</div></li><li id="ch17.lt6" class="half_rhythm"><div>Content of follow-up (for example clinical examination, serum CEA level, colonoscopy, liver-focused imaging, chest x-ray)</div></li><li id="ch17.lt7" class="half_rhythm"><div>Setting of follow-up (for example primary care or hospital)</div></li><li id="ch17.lt8" class="half_rhythm"><div>Personnel in charge of running clinic (for example consultant led or nurse led)</div></li></ul></td></tr><tr><th id="hd_b_ch17.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison</th><td headers="hd_b_ch17.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l3"><li id="ch17.lt9" class="half_rhythm"><div>Follow-up strategies compared to each other, for example:
|
|
<ul id="ch17.l4" class="circle"><li id="ch17.lt10" class="half_rhythm"><div>intensive versus less intensive</div></li><li id="ch17.lt11" class="half_rhythm"><div>hospital-based versus GP-based</div></li></ul></div></li><li id="ch17.lt12" class="half_rhythm"><div>No follow-up</div></li></ul></td></tr><tr><th id="hd_b_ch17.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_ch17.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical</b>
|
|
<ul id="ch17.l5"><li id="ch17.lt13" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt14" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li></ul>
|
|
<b>Important</b>
|
|
<ul id="ch17.l6"><li id="ch17.lt15" class="half_rhythm"><div>Local recurrence</div></li><li id="ch17.lt16" class="half_rhythm"><div>Distant metastasis</div></li><li id="ch17.lt17" class="half_rhythm"><div>Metachronous colorectal cancer</div></li><li id="ch17.lt18" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li><li id="ch17.lt19" class="half_rhythm"><div>Overall quality of life</div></li><li id="ch17.lt20" class="half_rhythm"><div>Procedure-related morbidity</div></li></ul></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CEA: carcinoembryonic antigen; GP: General Practitioner; TNM: cancer classification system, standing for tumour, nodal and metastasis stages.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17tab2"><div id="ch17.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of included studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Trial</th><th id="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">N</th><th id="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention</th><th id="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Control</th><th id="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Follow-up for survival (months)</th><th id="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Formal follow-up period</th><th id="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th></tr></thead><tbody><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref1" rid="ch17.s1.1.ref1">Augestad 2013</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Norway</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GP led follow-up</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Surgeon led follow-up</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median 24</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l7"><li id="ch17.lt21" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt22" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt23" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt24" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li><li id="ch17.lt25" class="half_rhythm"><div>Overall quality of life</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch17.s1.1.ref2" rid="ch17.s1.1.ref2">CEAwatch 2017</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>The Netherlands</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3223</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEA every 2 months, and annual CT of chest/abdomen during the first 3 years. Annual outpatient visits. CEA every 3 months in the 4th and fifth years.</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Netherlands (2008) follow-up guidelines: outpatient visits every 6 months for the first 3 years and annual visits in years 4 and 5. Liver US and CXR at each visit. CEA every 3–6 months in the first 3 years and annually in following 2 years.</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years (step down after 3)</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l8"><li id="ch17.lt26" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt27" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt28" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch17.s1.1.ref3" rid="ch17.s1.1.ref3">COLOFOL 2018</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>International</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2509</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEA 1 month Postoperatively then CEA; CT or MRI of the liver or PET scans, or both; as well as X-ray or CT of the lungs at 6, 12, 18, 24, and 36 months</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEA 1 month postoperatively then CEA; CT or MRI of the liver, or both; and X-ray/CT of the lungs 12 and 36 months after surgery</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l9"><li id="ch17.lt29" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt30" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt31" class="half_rhythm"><div>Local recurrence/Distant metastasis (colorectal cancer-specific recurrence)</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>UK</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1202</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l10"><li id="ch17.lt32" class="half_rhythm"><div>CEA follow-up group: CEA testing every 3 months for 2 years, then every 6 months for 3 years with a single CT scan of the chest/ abdomen/ pelvis if requested at study entry by clinician</div></li><li id="ch17.lt33" class="half_rhythm"><div>CT follow-up group: CT scan of the chest/ abdomen/ pelvis every 6 months for 2 years, then annually for 3 years, plus colonoscopy at 2 years</div></li><li id="ch17.lt34" class="half_rhythm"><div>CEA+CT follow-up group: both blood and imaging as above, plus colonoscopy at 2 years</div></li></ul></td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No scheduled follow-up except a single CT scan of the chest/ abdomen /pelvis if requested at study entry by a clinician</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median 41</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years (step down at 2 years)</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l11"><li id="ch17.lt35" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt36" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt37" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt38" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref5" rid="ch17.s1.1.ref5">GILDA 1998</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>International</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1228</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Clinic visits at 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, and 60 months, with history and clinical examination, FBC, CEA, and CA 19-9.</p>
|
|
<p>Colonoscopy and CXR at 12, 24, 36, 48, and 60 months. Liver US at 4, 8, 12, 16, 24, 36, 48, and 60 months. For rectal participants, pelvic CT at 4, 12, 24, and 48 months</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Clinic visits at 4, 8, 12, 16, 20, 24, 30, 42, 48, and 60 months, including history, examination, and CEA.</p>
|
|
<p>Colonoscopy at 12 and 48 months. Liver US at 4 and 16 months. Rectal cancer participants in addition had rectoscopy at 4 months, CXR at 12 months, and liver US at 8 and 16 months.</p>
|
|
<p>A single pelvic CT was allowed if required as a baseline after adjuvant treatment</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median 62</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l12"><li id="ch17.lt39" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt40" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt41" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt42" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li><li id="ch17.lt43" class="half_rhythm"><div>Overall quality of life</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref7" rid="ch17.s1.1.ref7">Kjeldsen 1997</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Denmark</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">597</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinic visits at 6, 12, 18, 30, 36, 48, 60, 120, 150, and 180 months after radical surgery. Tests included medical history, clinical examination, DRE, gynaecological examination, HaemoccultII test, colonoscopy, CXR, haemoglobin level, ESR, and liver enzymes</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Clinic visits at 60, 120, and 180 months.</p>
|
|
<p>Tests included medical history, clinical examination, DRE, gynaecological examination, Haemoccult-II test, colonoscopy, CXR, haemoglobin level, ESR, and liver enzymes</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NR</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l13"><li id="ch17.lt44" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt45" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt46" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt47" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li><li id="ch17.lt48" class="half_rhythm"><div>Overall quality of life</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref8" rid="ch17.s1.1.ref8">Mäkelä 1995</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Finland</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Flexible sigmoidoscopy with video imaging every 3 months, colonoscopy at 3 months (if not done pre-op), then annually. US of the liver and primary site at 6 months, then annually.</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Annual rigid sigmoidoscopy and barium enema for those with rectal or sigmoid cancers.</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median 60</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l14"><li id="ch17.lt49" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt50" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt51" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref9" rid="ch17.s1.1.ref9">Ohlsson 1995</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Sweden</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">107</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Clinic visits at 3-, 6-, 9-, 12-, 15-, 18-, 21-, 24-, 30-, 36-, 42-, 48-, and 60- month intervals. Performed at each visit were clinical exam, rigid proctosigmoidoscopy, CEA, alkaline phosphatase, gamma-glutaryl transferase, faecal haemoglobin, and CXR.</p>
|
|
<p>Examination of anastomosis (flexible sigmoidoscopy or colonoscopy) done at 9, 21, and 42 months. Colonoscopy at 3, 15, 30, and 60 months. CT of the pelvis at 3, 6, 12, 18, and 24 months.</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No follow-up visits planned.</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66 to 106</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l15"><li id="ch17.lt52" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt53" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt54" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt55" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref10" rid="ch17.s1.1.ref10">Pietra 1998</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">207</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinic visits at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months, then annually thereafter. Clinical examination, ultrasound, CEA, and CXR at each visit. Annual CT of the liver and colonoscopy.</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinic visits at 6 and 12 months, then annually. At each visit, clinical examination, CEA, and US. Annual CXR, colonoscopy, and CT.</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l16"><li id="ch17.lt56" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt57" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt58" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt59" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref11" rid="ch17.s1.1.ref11">Rodríguez-Moranta 2006</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Spain</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">259</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tests: history, examination, and bloods (including CEA), US/CT, CXR, and colonoscopy.</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tests: history, examination, and bloods (including CEA)</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l17"><li id="ch17.lt60" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt61" class="half_rhythm"><div>Colorectal cancer-specific survival</div></li><li id="ch17.lt62" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt63" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref12" rid="ch17.s1.1.ref12">Schoemaker 1998</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Australia</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">325</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Annual CXR, CT of the liver, and colonoscopy</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CXR, CT of the liver, and colonoscopy done at 5 years or if indicated</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l18"><li id="ch17.lt64" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt65" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt66" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref13" rid="ch17.s1.1.ref13">Secco 2002</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">337</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinic visits and serum CEA, abdomen/pelvic US scans, and CXR. Those with rectal carcinoma had rigid sigmoidoscopy and CXR.</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal follow-up programme done by physicians</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l19"><li id="ch17.lt67" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt68" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref14" rid="ch17.s1.1.ref14">Sobhani 2008</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>France</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">130</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PET performed at 9 and 15 months in addition to the conventional follow-up tests</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conventional follow-up</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.25 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l20"><li id="ch17.lt69" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref15" rid="ch17.s1.1.ref15">Strand 2011</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Sweden</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Nurse led 6 monthly visits for 3 years, then annually up to 5 years. Symptom enquiry occurred at each visit (bloods and CEA as indicated)</p>
|
|
<p>Abdomen US and CXR (replaced by CT in latter half of the study) at 1 and 3 years</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Surgeon led 6 monthly visits for 3 years, then annually up to 5 years. Tests were the same as for nurse-led.</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l21"><li id="ch17.lt70" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt71" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref16" rid="ch17.s1.1.ref16">Treasure 2014</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>UK</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">216</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A significant CEA rise triggered “second-look” surgery, with intention to remove any recurrence discovered</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No action taken on significant CEA rise</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NR</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l22"><li id="ch17.lt72" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt73" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt74" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref17" rid="ch17.s1.1.ref17">Wang 2009</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>China</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">326</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Colonoscopy at each visit</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Colonoscopy at six months, 30 months, and 60 months</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64-79</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l23"><li id="ch17.lt75" class="half_rhythm"><div>Overall survival</div></li><li id="ch17.lt76" class="half_rhythm"><div>Local recurrence/ distant metastasis (relapse-free survival)</div></li><li id="ch17.lt77" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease</div></li><li id="ch17.lt78" class="half_rhythm"><div>Procedure-related morbidity</div></li></ul></td></tr><tr><td headers="hd_h_ch17.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a class="bibr" href="#ch17.s1.1.ref18" rid="ch17.s1.1.ref18">Wattchow 2006</a> (reported in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffery 2016</a>)</p>
|
|
<p>RCT</p>
|
|
<p>Australia</p>
|
|
</td><td headers="hd_h_ch17.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">203</td><td headers="hd_h_ch17.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Primary care follow-up</td><td headers="hd_h_ch17.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Secondary care follow-up</td><td headers="hd_h_ch17.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_ch17.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 years</td><td headers="hd_h_ch17.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l24"><li id="ch17.lt79" class="half_rhythm"><div>Overall quality of life</div></li></ul></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CXR: chest X-ray; CT: computed tomography; DRE: digital rectal examination; ESR: erythrocyte sedimentation rate; FBC: full blood count; GP: General Practitioner; MRI: magnetic resonance imaging; NR: not reported; PET: positron emission tomography; RCT: randomised controlled trial; US: ultrasound</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobch17fig1"><div id="ch17.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Summary%20of%20follow-up%20protocols%20compared%20in%20trials.&p=BOOKS&id=559930_ch17f1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17f1.jpg" alt="Figure 1. Summary of follow-up protocols compared in trials." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Summary of follow-up protocols compared in trials</span></h3><div class="caption"><p>CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CT: computed tomography; FBC: full blood count; FOB: faecal occult blood; PET: positron emission tomography; US: ultrasound</p></div></div></article><article data-type="table-wrap" id="figobch17appatab1"><div id="ch17.appa.tab1" class="table"><h3><span class="label">Table 3</span><span class="title">Review protocol for the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appa.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Field (based on <a href="http://www.prisma-statement.org/Extensions/Protocols.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PRISMA-P)</a></th><th id="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">What are the optimal methods and frequencies of follow-up to detect recurrence after potentially curative surgical treatment for non-metastatic colorectal cancer?</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To determine the optimal methods and frequencies of follow-up after potentially curative surgical treatment to detect recurrence for people who have had non-metastatic colorectal cancer.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population/disease/condition/issue/domain</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults who have undergone surgical or endoscopic resection for non-metastatic colorectal cancer (colon cancer or rectal cancer) with curative intent (with or without adjuvant therapy):
|
|
<ul id="ch17.l54"><li id="ch17.lt109" class="half_rhythm"><div>T any</div></li><li id="ch17.lt110" class="half_rhythm"><div>N any</div></li><li id="ch17.lt111" class="half_rhythm"><div>M0</div></li></ul></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s)/exposure(s)/progno stic factor(s)</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l55"><li id="ch17.lt112" class="half_rhythm"><div>Follow-up strategy taking into consideration one or more of the following elements:
|
|
<ul id="ch17.l56" class="circle"><li id="ch17.lt113" class="half_rhythm"><div>Intensity/frequency of follow-up</div></li><li id="ch17.lt114" class="half_rhythm"><div>Duration of follow-up</div></li><li id="ch17.lt115" class="half_rhythm"><div>Content of follow-up (for example clinical examination, serum CEA level, colonoscopy, liver-focused imaging, chest x-ray)</div></li><li id="ch17.lt116" class="half_rhythm"><div>Setting of follow-up (for example primary care or hospital)</div></li><li id="ch17.lt117" class="half_rhythm"><div>Personnel in charge of running clinic (for example consultant led or nurse led)</div></li></ul></div></li></ul></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – comparator(s)/control or reference (gold) standard</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l57"><li id="ch17.lt118" class="half_rhythm"><div>Follow-up strategies compared to each other, for example:
|
|
<ul id="ch17.l58" class="circle"><li id="ch17.lt119" class="half_rhythm"><div>intensive versus less intensive</div></li><li id="ch17.lt120" class="half_rhythm"><div>hospital-based versus GP-based</div></li></ul></div></li><li id="ch17.lt121" class="half_rhythm"><div>No follow-up</div></li></ul></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical outcomes</b>
|
|
<ul id="ch17.l59"><li id="ch17.lt122" class="half_rhythm"><div>Overall survival (MID: any statistically significant difference)</div></li><li id="ch17.lt123" class="half_rhythm"><div>Colorectal cancer-specific survival (MID: any statistically significant difference)</div></li></ul>
|
|
<b>Important outcomes</b>
|
|
<ul id="ch17.l60"><li id="ch17.lt124" class="half_rhythm"><div>Local recurrence (MID: any statistically significant difference)</div></li><li id="ch17.lt125" class="half_rhythm"><div>Distant metastasis (MID: any statistically significant difference)</div></li><li id="ch17.lt126" class="half_rhythm"><div>Metachronous colorectal cancer (MID: any statistically significant difference)</div></li><li id="ch17.lt127" class="half_rhythm"><div>Resectability of recurrent local or metastatic disease (MID: any statistically significant difference)</div></li><li id="ch17.lt128" class="half_rhythm"><div>Overall quality of life measured using validated scales (MID: from published literature)</div></li><li id="ch17.lt129" class="half_rhythm"><div>Procedure-related morbidity (MID: any statistically significant difference)</div></li></ul>
|
|
Quality of life MIDs from the literature:
|
|
<ul id="ch17.l61"><li id="ch17.lt130" class="half_rhythm"><div>EORTC QLQ-C30: 5 points*</div></li><li id="ch17.lt131" class="half_rhythm"><div>EORTC QLQ-CR29: 5 points*</div></li><li id="ch17.lt132" class="half_rhythm"><div>EORTC QLQ-CR38: 5 points*</div></li><li id="ch17.lt133" class="half_rhythm"><div>EQ-5D: 0.09 using FACT-G quintiles</div></li><li id="ch17.lt134" class="half_rhythm"><div>FACT-C: 5 points*</div></li><li id="ch17.lt135" class="half_rhythm"><div>FACT-G: 5 points*</div></li><li id="ch17.lt136" class="half_rhythm"><div>SF-12: > 3.77 for the mental component summary and > 3.29 for the physical component summary</div></li><li id="ch17.lt137" class="half_rhythm"><div>SF-36: > 7.1 for the physical functioning scale, > 4.9 for the bodily pain scale, and > 7.2 for the physical component summary</div></li></ul>
|
|
*Confirmed with guideline committee.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch17.l62"><li id="ch17.lt138" class="half_rhythm"><div>Systematic reviews of RCTs</div></li><li id="ch17.lt139" class="half_rhythm"><div>RCTs</div></li><li id="ch17.lt140" class="half_rhythm"><div>Comparative observational studies if eligible RCTs are not available</div></li></ul></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inclusion criteria:
|
|
<ul id="ch17.l63"><li id="ch17.lt141" class="half_rhythm"><div>English-language</div></li><li id="ch17.lt142" class="half_rhythm"><div>Published full text papers</div></li><li id="ch17.lt143" class="half_rhythm"><div>All settings will be considered that consider medications and treatments available in the UK</div></li><li id="ch17.lt144" class="half_rhythm"><div>Studies published post 2000</div></li></ul>
|
|
Studies published 2000 onwards will be considered for this review question because the guideline committee considered that follow-up methods have evolved and evidence published prior to 2000 would no longer be relevant.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity/sub-group analysis, or meta-regression</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None identified.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening/selection/analysis</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Sifting, data extraction, appraisal of methodological quality and GRADE assessment will be performed by the systematic reviewer. Dual sifting will be undertaken for this question for a random 10% sample of the titles and abstracts identified by the search. Resolution of any disputes will be with the senior systematic reviewer and the Topic Advisor.</p>
|
|
<p>Quality control will be performed by the senior systematic reviewer</p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Pairwise meta-analyses was performed using Cochrane Review Manager (RevMan5).</p>
|
|
<p>‘GRADEpro’ was be used to assess the quality of evidence for each outcome.</p>
|
|
<p>NGA STAR software was used for study sifting, data extraction, recording quality assessment using checklists and generating bibliographies/citations.</p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Potential sources to be searched (to be confirmed by Information Scientist): Medline, Medline In-Process, CCTR, CDSR, DARE, HTA, Embase</p>
|
|
<p>Limits (e.g. date, study design):
|
|
<ul id="ch17.l64"><li id="ch17.lt145" class="half_rhythm"><div>Apply standard animal/non-English language exclusion</div></li><li id="ch17.lt146" class="half_rhythm"><div>Limit to RCTs and systematic reviews in first instance, but download all results</div></li><li id="ch17.lt147" class="half_rhythm"><div>Dates: from 2000</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an update</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10060" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.nice.org<wbr style="display:inline-block"></wbr>​.uk/guidance/indevelopment/gid-ng10060</a>
|
|
</p>
|
|
<p>Developer: NGA</p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for one database</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see <a href="#ch17.appb">appendix B</a>.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms/duplicate</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format will be used, and published as <a href="#ch17.appd">appendix D</a> (clinical evidence tables) or <a href="#ch17.apph">H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see evidence tables in <a href="#ch17.appd">appendix D</a> (clinical evidence tables) or <a href="#ch17.apph">H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome/study level</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></p>
|
|
<p>Appraisal of methodological quality:</p>
|
|
<p>The methodological quality of each study will be assessed using an appropriate checklist:
|
|
<ul id="ch17.l65"><li id="ch17.lt148" class="half_rhythm"><div>CASP for systematic reviews</div></li><li id="ch17.lt149" class="half_rhythm"><div>Cochrane risk of bias tool for RCTs</div></li><li id="ch17.lt150" class="half_rhythm"><div>ROBINS-I for non-randomised studies</div></li></ul>
|
|
The quality of the evidence for an outcome (i.e. across studies) will be assessed using GRADE.</p>
|
|
<p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.gradeworkinggroup.org/</a></p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>Synthesis of data:</b>
|
|
</p>
|
|
<p>Pairwise meta-analysis of randomised trials will be conducted where appropriate.</p>
|
|
<p>When meta-analysing continuous data, final and change scores will be pooled if baselines are comparable. If any studies report both, the method used in the majority of studies will be analysed.</p>
|
|
<p>
|
|
<b>Minimally important differences:</b>
|
|
</p>
|
|
<p>The guideline committee identified statistically significant differences as appropriate indicators for clinical significance for all outcomes except quality of life for which published MIDs from literature will be used (see outcomes section for more information).</p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>If sufficient relevant RCT evidence is available, publication bias will be explored using RevMan software to examine funnel plots.</p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assessment of confidence in cumulative evidence</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale/context – what is known</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A multidisciplinary committee developed the guideline. The committee was convened by The National Guideline Alliance and chaired by Peter Hoskin in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>Staff from The NGA undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the guideline in collaboration with the committee. For details please see Supplement 1: methods.</p>
|
|
</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding/support</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The NGA is funded by NICE and hosted by Royal College of Obstetricians and Gynaecologists</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The NGA is funded by NICE and hosted by Royal College of Obstetricians and Gynaecologists</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds the NGA to develop guidelines for those working in the NHS, public health and social care in England.</td></tr><tr><td headers="hd_h_ch17.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_ch17.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered with PROSPERO</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CASP: critical appraisal skills programme; CCTR: Cochrane controlled trials register; CDSR: Cochrane database of systematic reviews; CEA: carcinoembryonic antigen; DARE: Database of Abstracts of Reviews of Effects; EQ-5D: EuroQol five dimensions questionnaire; EORTC QLQ-C30: European Organisation for Re-search and Treatment of Cancer Quality of Life Questionnaire Core 30 Items; EORTC QLQ-CR29: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire colorectal cancer module (29 items); EORTC QLQ-CR38: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire colorectal cancer module (38 items); FACT-C: Functional Assessment of Cancer Therapy questionnaire (colorectal cancer); FACT-G: Functional Assessment of Cancer Therapy questionnaire (general); GP: General Practitioner; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HTA: Health Technology Assessment; MID: minimal important difference; NGA: National Guidelines Alliance; NHS: National Health Service; NICE: National Institute for Health and Clinical Excellence; PRISMA-P: Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols; PROSPERO: International prospective register of systematic reviews; RCT: randomised controlled trial; SF-12: 12-Item Short Form Survey; SF-36: 36-Item Short Form Survey</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appbtab1"><div id="ch17.appb.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#</th><th id="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search</th></tr></thead><tbody><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(exp colorectal cancer/ or exp colon tumor/ or exp rectum tumor/) use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp colorectal neoplasms/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((colorect* or colo rect* or colon or colonic or rectal or rectum) adj3 (adenocarcinoma* or cancer* or carcinoma* or malignan* or neoplas* or oncolog* or tumo?r*)).tw.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-3</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp recurrence/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Neoplasm recurrence, local/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disease progression/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cancer recurrence/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recurrent disease/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tumor recurrence/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">postoperative care/</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Recurr* or relaps* or reappear* or post-operat* or postoperat* or post-surg* or postsurg* or post-hosp* or posthosp*).tw.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/5-12</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 and 13</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp aftercare/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp *aftercare/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(follow up or followup).ti.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((follow up or followup) adj3 (hospital* or post-hospital*or operat* or post-operat* or resection* or surg* or post-surg* or therap* or post-therap* or postherp* or posttherap* or treatment* or post-treatment or posttreatment)).tw.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((follow up or followup) adj3 (plan* or program* or protocol* or regime* or schedule* or strateg*)).tw.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp patient monitoring/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Monitoring, Physiologic/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">population surveillance/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(surveill* adj3 (colonoscop* or guideline* or follow up or followup or plan* or post-operat* or postoperat* or post-treatment* or posttreatment* or practice* or program* or protocol* schedule* or strateg*)).tw.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(re-examin* or reexamin* or periodic examin* or regular examin* or checkup* or check-up*).tw.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/15-24</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 and 25</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Letter/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Editorial/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">News/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Historical Article/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comment/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case Report/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/ or case study/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/27-38</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">random*.ti,ab.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/40-42</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 not 43</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">nonhuman/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental Animal/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal model/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/ use ppez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/ use emez</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/44-56</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 not 57</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 58 to (english language and yr=“2000-current”)</td></tr><tr><td headers="hd_h_ch17.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch17.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">remove duplicates from 59</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch17appbtab2"><div id="ch17.appb.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appb.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#</th><th id="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search</th></tr></thead><tbody><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Colorectal Neoplasms] explode all trees</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((colorect* or colo rect* or colon or colonic or rectal or rectum) near/3 (adenocarcinoma* or cancer* or carcinoma* or malignan* or neoplas* or oncolog* or tumo?r*)):ti,ab,kw</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 or #2</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Recurrence] explode all trees</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Neoplasm Recurrence, Local] this term only</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Disease Progression] this term only</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Postoperative Care] this term only</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Recurr* or relaps* or reappear* or post-operat* or postoperat* or post-surg* or postsurg* or post-hosp* or posthosp*):ti,ab,kw</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">{or #4-#8}</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3 and #9</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Aftercare] explode all trees</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(follow up or followup):ti</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((follow up or followup) near/3 (hospital* or post-hospital*or operat* or post-operat* or resection* or surg* or post-surg* or therap* or post-therap* or postherp* or posttherap* or treatment* or post-treatment or posttreatment)):ti,ab,kw</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((follow up or followup) near/3 (plan* or program* or protocol* or regime* or schedule* or strateg*)):ti,ab,kw</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Monitoring, Physiologic] explode all trees</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Population Surveillance] this term only</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(surveill* near/3 (colonoscop* or guideline* or follow up or followup or plan* or post-operat* or postoperat* or post-treatment* or posttreatment* or practice* or program* or protocol* schedule* or strateg*)):ti,ab,kw</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(re-examin* or reexamin* or periodic examin* or regular examin* or checkup* or check-up*):ti,ab,kw</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">{or #11-#18}</td></tr><tr><td headers="hd_h_ch17.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_ch17.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10 and #19 Publication Year from 2000 to 2018</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobch17appcfig1"><div id="ch17.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Study%20selection%20flow%20chart.&p=BOOKS&id=559930_ch17appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appcf1.jpg" alt="Figure 2. Study selection flow chart." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Study selection flow chart</span></h3></div></article><article data-type="fig" id="figobch17appefig1"><div id="ch17.appe.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Comparison%201%3A%20More%20intensive%20versus%20less%20intensive%20follow-up%20%02013%20Overall%20survival%20(follow-up%2024%20to%2066%20months).&p=BOOKS&id=559930_ch17appef1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef1.jpg" alt="Figure 3. Comparison 1: More intensive versus less intensive follow-up – Overall survival (follow-up 24 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Comparison 1: More intensive versus less intensive follow-up – Overall survival (follow-up 24 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig2"><div id="ch17.appe.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Comparison%201%3A%20More%20intensive%20versus%20less%20intensive%20follow-up%20%02013%20Colorectal%207%20cancer-specific%20survival%20(follow-up%2024%20to%2066%20months).&p=BOOKS&id=559930_ch17appef2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef2.jpg" alt="Figure 4. Comparison 1: More intensive versus less intensive follow-up – Colorectal 7 cancer-specific survival (follow-up 24 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Comparison 1: More intensive versus less intensive follow-up – Colorectal 7 cancer-specific survival (follow-up 24 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig3"><div id="ch17.appe.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Comparison%201%3A%20More%20intensive%20versus%20less%20intensive%20follow-up%20%02013%20Relapse-free%20survival%20(follow-up%2024%20to%2066%20months).&p=BOOKS&id=559930_ch17appef3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef3.jpg" alt="Figure 5. Comparison 1: More intensive versus less intensive follow-up – Relapse-free survival (follow-up 24 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Comparison 1: More intensive versus less intensive follow-up – Relapse-free survival (follow-up 24 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig4"><div id="ch17.appe.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Comparison%201%3A%20More%20intensive%20versus%20less%20intensive%20follow-up%20%02013%20Resectable%20recurrent%20disease%20(follow-up%2024%20to%2066%20months).&p=BOOKS&id=559930_ch17appef4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef4.jpg" alt="Figure 6. Comparison 1: More intensive versus less intensive follow-up – Resectable recurrent disease (follow-up 24 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Comparison 1: More intensive versus less intensive follow-up – Resectable recurrent disease (follow-up 24 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; M-H: Mantel-Haenszel</p></div></div></article><article data-type="fig" id="figobch17appefig5"><div id="ch17.appe.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Comparison%201%3A%20More%20intensive%20versus%20less%20intensive%20follow-up%20%02013%20Procedure-related%20morbidity%20(follow-up%2064%20months).&p=BOOKS&id=559930_ch17appef5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef5.jpg" alt="Figure 7. Comparison 1: More intensive versus less intensive follow-up – Procedure-related morbidity (follow-up 64 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Comparison 1: More intensive versus less intensive follow-up – Procedure-related morbidity (follow-up 64 months)</span></h3><div class="caption"><p>CI: confidence interval;</p></div></div></article><article data-type="fig" id="figobch17appefig6"><div id="ch17.appe.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%208.%20Comparison%202%3A%20More%20visits%20or%20tests%20versus%20fewer%20visits%20or%20tests%20%02013%20Overall%20survival%20(follow-up%2041%20to%2064%20months).&p=BOOKS&id=559930_ch17appef6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef6.jpg" alt="Figure 8. Comparison 2: More visits or tests versus fewer visits or tests – Overall survival (follow-up 41 to 64 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 8</span><span class="title">Comparison 2: More visits or tests versus fewer visits or tests – Overall survival (follow-up 41 to 64 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig7"><div id="ch17.appe.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%209.%20Comparison%202%3A%20More%20visits%20or%20tests%20versus%20fewer%20visits%20or%20tests%20%02013%20Colorectal%20cancer-specific%20survival%20(follow-up%2041%20to%2064%20months).&p=BOOKS&id=559930_ch17appef7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef7.jpg" alt="Figure 9. Comparison 2: More visits or tests versus fewer visits or tests – Colorectal cancer-specific survival (follow-up 41 to 64 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 9</span><span class="title">Comparison 2: More visits or tests versus fewer visits or tests – Colorectal cancer-specific survival (follow-up 41 to 64 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig8"><div id="ch17.appe.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2010.%20Comparison%202%3A%20More%20visits%20or%20tests%20versus%20fewer%20visits%20or%20tests%20%02013%20Relapse-free%20survival%20(follow-up%2041%20to%2064%20months).&p=BOOKS&id=559930_ch17appef8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef8.jpg" alt="Figure 10. Comparison 2: More visits or tests versus fewer visits or tests – Relapse-free survival (follow-up 41 to 64 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 10</span><span class="title">Comparison 2: More visits or tests versus fewer visits or tests – Relapse-free survival (follow-up 41 to 64 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig9"><div id="ch17.appe.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2011.%20Comparison%202%3A%20More%20visits%20or%20tests%20versus%20fewer%20visits%20or%20tests%20%02013%20Resectable%20recurrent%20disease%20(follow-up%2041%20to%2064%20months).&p=BOOKS&id=559930_ch17appef9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef9.jpg" alt="Figure 11. Comparison 2: More visits or tests versus fewer visits or tests – Resectable recurrent disease (follow-up 41 to 64 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 11</span><span class="title">Comparison 2: More visits or tests versus fewer visits or tests – Resectable recurrent disease (follow-up 41 to 64 months)</span></h3><div class="caption"><p>CI: confidence interval; M-H: Mantel-Haenszel</p></div></div></article><article data-type="fig" id="figobch17appefig10"><div id="ch17.appe.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2012.%20Comparison%202%3A%20More%20visits%20or%20tests%20versus%20fewer%20visits%20or%20tests%20%02013%20Procedure-related%20morbidity%20(follow-up%2064%20months).&p=BOOKS&id=559930_ch17appef10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef10.jpg" alt="Figure 12. Comparison 2: More visits or tests versus fewer visits or tests – Procedure-related morbidity (follow-up 64 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 12</span><span class="title">Comparison 2: More visits or tests versus fewer visits or tests – Procedure-related morbidity (follow-up 64 months)</span></h3><div class="caption"><p>CI: confidence interval</p></div></div></article><article data-type="fig" id="figobch17appefig11"><div id="ch17.appe.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2013.%20Comparison%203%3A%20Visits%20or%20tests%20versus%20minimal%20or%20no%20follow-up%20%02013%20Overall%20survival%20(follow-up%2041%20to%2066%20months).&p=BOOKS&id=559930_ch17appef11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef11.jpg" alt="Figure 13. Comparison 3: Visits or tests versus minimal or no follow-up – Overall survival (follow-up 41 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 13</span><span class="title">Comparison 3: Visits or tests versus minimal or no follow-up – Overall survival (follow-up 41 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig12"><div id="ch17.appe.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2014.%20Comparison%203%3A%20Visits%20or%20tests%20versus%20minimal%20or%20no%20follow-up%20%02013%20Colorectal%20cancer-specific%20survival%20(follow-up%2041%20to%2066%20months).&p=BOOKS&id=559930_ch17appef12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef12.jpg" alt="Figure 14. Comparison 3: Visits or tests versus minimal or no follow-up – Colorectal cancer-specific survival (follow-up 41 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 14</span><span class="title">Comparison 3: Visits or tests versus minimal or no follow-up – Colorectal cancer-specific survival (follow-up 41 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig13"><div id="ch17.appe.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2015.%20Comparison%203%3A%20Visits%20or%20tests%20versus%20minimal%20or%20no%20follow-up%20%02013%20Relapse-free%20survival%20(follow-up%2041%20to%2066%20months).&p=BOOKS&id=559930_ch17appef13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef13.jpg" alt="Figure 15. Comparison 3: Visits or tests versus minimal or no follow-up – Relapse-free survival (follow-up 41 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 15</span><span class="title">Comparison 3: Visits or tests versus minimal or no follow-up – Relapse-free survival (follow-up 41 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig14"><div id="ch17.appe.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2016.%20Comparison%203%3A%20Visits%20or%20tests%20versus%20minimal%20or%20no%20follow-up%20%02013%20Resectable%20recurrent%20disease%20(follow-up%2041%20to%2066%20months).&p=BOOKS&id=559930_ch17appef14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef14.jpg" alt="Figure 16. Comparison 3: Visits or tests versus minimal or no follow-up – Resectable recurrent disease (follow-up 41 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 16</span><span class="title">Comparison 3: Visits or tests versus minimal or no follow-up – Resectable recurrent disease (follow-up 41 to 66 months)</span></h3><div class="caption"><p>CI: confidence interval; M-H: Mantel-Haenszel</p></div></div></article><article data-type="fig" id="figobch17appefig15"><div id="ch17.appe.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2017.%20Comparison%204%3A%20More%20liver%20imaging%20versus%20less%20liver%20imaging%20%02013%20Overall%20survival%20(follow-up%2048%20to%2060%20months).&p=BOOKS&id=559930_ch17appef15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef15.jpg" alt="Figure 17. Comparison 4: More liver imaging versus less liver imaging – Overall survival (follow-up 48 to 60 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 17</span><span class="title">Comparison 4: More liver imaging versus less liver imaging – Overall survival (follow-up 48 to 60 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig16"><div id="ch17.appe.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2018.%20Comparison%204%3A%20More%20liver%20imaging%20versus%20less%20liver%20imaging%20%02013%20Colorectal%20cancer-specific%20survival%20(follow-up%2048%20to%2060%20months).&p=BOOKS&id=559930_ch17appef16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef16.jpg" alt="Figure 18. Comparison 4: More liver imaging versus less liver imaging – Colorectal cancer-specific survival (follow-up 48 to 60 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 18</span><span class="title">Comparison 4: More liver imaging versus less liver imaging – Colorectal cancer-specific survival (follow-up 48 to 60 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig17"><div id="ch17.appe.fig17" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2019.%20Comparison%204%3A%20More%20liver%20imaging%20versus%20less%20liver%20imaging%20%02013%20Relapse-free%20survival%20(follow-up%2048%20to%2060%20months).&p=BOOKS&id=559930_ch17appef17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef17.jpg" alt="Figure 19. Comparison 4: More liver imaging versus less liver imaging – Relapse-free survival (follow-up 48 to 60 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 19</span><span class="title">Comparison 4: More liver imaging versus less liver imaging – Relapse-free survival (follow-up 48 to 60 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig18"><div id="ch17.appe.fig18" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2020.%20Comparison%204%3A%20More%20liver%20imaging%20versus%20less%20liver%20imaging%20%02013%20Resectable%20recurrent%20disease%20(follow-up%2048%20to%2060%20months).&p=BOOKS&id=559930_ch17appef18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef18.jpg" alt="Figure 20. Comparison 4: More liver imaging versus less liver imaging – Resectable recurrent disease (follow-up 48 to 60 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 20</span><span class="title">Comparison 4: More liver imaging versus less liver imaging – Resectable recurrent disease (follow-up 48 to 60 months)</span></h3><div class="caption"><p>CI: confidence interval; M-H: Mantel-Haenszel</p></div></div></article><article data-type="fig" id="figobch17appefig19"><div id="ch17.appe.fig19" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2021.%20Comparison%205%3A%20CEA%20tests%20versus%20no%20CEA%20tests%20%02013%20Overall%20survival%20(follow-up%2066%20months).&p=BOOKS&id=559930_ch17appef19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef19.jpg" alt="Figure 21. Comparison 5: CEA tests versus no CEA tests – Overall survival (follow-up 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 21</span><span class="title">Comparison 5: CEA tests versus no CEA tests – Overall survival (follow-up 66 months)</span></h3><div class="caption"><p>CEA: carcinoembryonic antigen; CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig20"><div id="ch17.appe.fig20" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2022.%20Comparison%205%3A%20CEA%20tests%20versus%20no%20CEA%20tests%20%02013%20Colorectal%20cancer-specific%20survival%20(follow-up%2066%20months).&p=BOOKS&id=559930_ch17appef20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef20.jpg" alt="Figure 22. Comparison 5: CEA tests versus no CEA tests – Colorectal cancer-specific survival (follow-up 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 22</span><span class="title">Comparison 5: CEA tests versus no CEA tests – Colorectal cancer-specific survival (follow-up 66 months)</span></h3><div class="caption"><p>CEA: carcinoembryonic antigen; CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig21"><div id="ch17.appe.fig21" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2023.%20Comparison%205%3A%20CEA%20tests%20versus%20no%20CEA%20tests%20%02013%20Relapse-free%20survival%20(follow-up%2066%20months).&p=BOOKS&id=559930_ch17appef21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef21.jpg" alt="Figure 23. Comparison 5: CEA tests versus no CEA tests – Relapse-free survival (follow-up 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 23</span><span class="title">Comparison 5: CEA tests versus no CEA tests – Relapse-free survival (follow-up 66 months)</span></h3><div class="caption"><p>CEA: carcinoembryonic antigen; CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig22"><div id="ch17.appe.fig22" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2024.%20Comparison%205%3A%20CEA%20tests%20versus%20no%20CEA%20tests%20%02013%20Resectable%20recurrent%20disease%20(follow-up%2041%20to%2066%20months).&p=BOOKS&id=559930_ch17appef22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef22.jpg" alt="Figure 24. Comparison 5: CEA tests versus no CEA tests – Resectable recurrent disease (follow-up 41 to 66 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 24</span><span class="title">Comparison 5: CEA tests versus no CEA tests – Resectable recurrent disease (follow-up 41 to 66 months)</span></h3><div class="caption"><p>CEA: carcinoembryonic antigen; CI: confidence interval; M-H: Mantel-Haenszel</p></div></div></article><article data-type="fig" id="figobch17appefig23"><div id="ch17.appe.fig23" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2025.%20Comparison%206%3A%20Nurse%20or%20GP%20led%20follow-up%20versus%20surgeon%20led%20follow-up%20%02013%20Overall%20survival%20(follow-up%2024%20to%2060%20months).&p=BOOKS&id=559930_ch17appef23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef23.jpg" alt="Figure 25. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Overall survival (follow-up 24 to 60 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 25</span><span class="title">Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Overall survival (follow-up 24 to 60 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig24"><div id="ch17.appe.fig24" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2026.%20Comparison%206%3A%20Nurse%20or%20GP%20led%20follow-up%20versus%20surgeon%20led%20follow-up%20%02013%20Colorectal%20cancer-specific%20survival%20(follow-up%2024%20months).&p=BOOKS&id=559930_ch17appef24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef24.jpg" alt="Figure 26. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Colorectal cancer-specific survival (follow-up 24 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 26</span><span class="title">Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Colorectal cancer-specific survival (follow-up 24 months)</span></h3><div class="caption"><p>CI: confidence interval; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig25"><div id="ch17.appe.fig25" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2027.%20Comparison%206%3A%20Nurse%20or%20GP%20led%20follow-up%20versus%20surgeon%20led%20follow-up%20%02013%20Relapse-free%20survival%20(follow-up%2024%20to%2060%20months).&p=BOOKS&id=559930_ch17appef25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef25.jpg" alt="Figure 27. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Relapse-free survival (follow-up 24 to 60 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 27</span><span class="title">Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Relapse-free survival (follow-up 24 to 60 months)</span></h3><div class="caption"><p>CI: confidence interval; df: degrees of freedom; IV: inverse variance; SE: standard error</p></div></div></article><article data-type="fig" id="figobch17appefig26"><div id="ch17.appe.fig26" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2028.%20Comparison%206%3A%20Nurse%20or%20GP%20led%20follow-up%20versus%20surgeon%20led%20follow-up%20%02013%20Resectable%20recurrent%20disease%20(follow-up%2024%20months).&p=BOOKS&id=559930_ch17appef26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559930/bin/ch17appef26.jpg" alt="Figure 28. Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Resectable recurrent disease (follow-up 24 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 28</span><span class="title">Comparison 6: Nurse or GP led follow-up versus surgeon led follow-up – Resectable recurrent disease (follow-up 24 months)</span></h3><div class="caption"><p>CI: confidence interval; M-H: Mantel-Haenszel</p></div></div></article><article data-type="table-wrap" id="figobch17appftab1"><div id="ch17.appf.tab1" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence profile for comparison 1: More intensive versus less intensive follow-up</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appf.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appf.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appf.tab1_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch17.appf.tab1_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch17.appf.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch17.appf.tab1_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab1_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch17.appf.tab1_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab1_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th headers="hd_h_ch17.appf.tab1_1_1_1_1" id="hd_h_ch17.appf.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other considerations</th><th headers="hd_h_ch17.appf.tab1_1_1_1_2" id="hd_h_ch17.appf.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intensive follow-up</th><th headers="hd_h_ch17.appf.tab1_1_1_1_2" id="hd_h_ch17.appf.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Less intensive follow-up</th><th headers="hd_h_ch17.appf.tab1_1_1_1_3" id="hd_h_ch17.appf.tab1_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relative (95% CI)</th><th headers="hd_h_ch17.appf.tab1_1_1_1_3" id="hd_h_ch17.appf.tab1_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute (95% CI)</th></tr></thead><tbody><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall survival (event is death from any cause; follow-up 24 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5989</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6268</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.89 (0.80 to 0.99)</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 87% (86% to 89%) overall survival with intensive versus 86% without<sup>5</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer-specific survival (event is death from colorectal cancer; follow-up 24 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5607</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5893</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.92 (0.80 to 1.06)</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 90% (88% to 91%) colorectal cancer-specific survival with intensive versus 89% without<sup>5</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Relapse-free survival (event is any colorectal cancer recurrence; follow-up 24 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4140</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4606</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 1.07 (0.96 to 1.19)</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 80% (78% to 82%) relapse with intensive versus 81% without<sup>5</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Local recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Distant recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Metachronous colorectal cancer</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Resectable recurrent disease (Salvage surgery; follow-up 24 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>318/2897</p>
|
|
<p>(11.0%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>140/2260</p>
|
|
<p>(6.2%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.96 (1.52 to 2.52)</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59 more per 1,000 (from 32 more to 94 more)</td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall quality of life</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_h_ch17.appf.tab1_1_1_2_3 hd_h_ch17.appf.tab1_1_1_2_4 hd_h_ch17.appf.tab1_1_1_2_5 hd_h_ch17.appf.tab1_1_1_2_6 hd_h_ch17.appf.tab1_1_1_2_7 hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_h_ch17.appf.tab1_1_1_2_9 hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_h_ch17.appf.tab1_1_1_2_11 hd_h_ch17.appf.tab1_1_1_1_4 hd_h_ch17.appf.tab1_1_1_1_5" id="hd_b_ch17.appf.tab1_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Procedure-related complications (Colonoscopy complications; follow-up 64 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_1 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_2 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_3 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_4 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_5 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_6 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious <sup>4</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_1 hd_h_ch17.appf.tab1_1_1_2_7 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_8 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3/1204</p>
|
|
<p>(0.2%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab1_1_1_1_2 hd_h_ch17.appf.tab1_1_1_2_9 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/357</p>
|
|
<p>(0.0%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_10 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 3.66 (0.25 to 54.28)</td><td headers="hd_h_ch17.appf.tab1_1_1_1_3 hd_h_ch17.appf.tab1_1_1_2_11 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 more per 1,000 (from 1 fewer to 51 more)<sup>6</sup></td><td headers="hd_h_ch17.appf.tab1_1_1_1_4 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch17.appf.tab1_1_1_1_5 hd_b_ch17.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; HR: hazard ratio; OR: odds ratio; RR: relative risk</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch17.appf.tab1_1"><p class="no_margin">Downgraded due to lack of blinding in 5 trials leading to high risk of ascertainment bias for cause of death.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch17.appf.tab1_2"><p class="no_margin">Downgraded due to lack of blinding in 4 trials and lack of allocation concealment in 3 trials.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch17.appf.tab1_3"><p class="no_margin">High risk of bias due to lack of blinding of participants and outcome assessment</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch17.appf.tab1_4"><p class="no_margin">Number of events <300</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch17.appf.tab1_5"><p class="no_margin">Control group rates take from <a class="bibr" href="#ch17.s1.1.ref3" rid="ch17.s1.1.ref3">COLOFOL 2018</a> trial</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch17.appf.tab1_6"><p class="no_margin">Assumed control group risk of 0.1%</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appftab2"><div id="ch17.appf.tab2" class="table"><h3><span class="label">Table 6</span><span class="title">Clinical evidence profile for comparison 2: More visits or tests versus fewer visits or tests</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appf.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appf.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appf.tab2_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch17.appf.tab2_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch17.appf.tab2_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch17.appf.tab2_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab2_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch17.appf.tab2_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab2_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th headers="hd_h_ch17.appf.tab2_1_1_1_1" id="hd_h_ch17.appf.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other considerations</th><th headers="hd_h_ch17.appf.tab2_1_1_1_2" id="hd_h_ch17.appf.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">More visits or tests</th><th headers="hd_h_ch17.appf.tab2_1_1_1_2" id="hd_h_ch17.appf.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Fewer visits or tests</th><th headers="hd_h_ch17.appf.tab2_1_1_1_3" id="hd_h_ch17.appf.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relative (95% CI)</th><th headers="hd_h_ch17.appf.tab2_1_1_1_3" id="hd_h_ch17.appf.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute (95% CI)</th></tr></thead><tbody><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall survival (event is death from any cause; follow-up 41 months to 64 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4136</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5025</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.85 (0.74 to 0.97)</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 88% (86% to 89%) overall survival with more visits versus 86% with fewer<sup>6</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer-specific survival (event is death from colorectal cancer; follow-up 41 months to 64 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3976</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4863</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.88 (0.75 to 1.03)</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 90% (89% to 92%) cancers-pecific survival with more visits versus 89% with fewer<sup>6</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Relapse-free survival (event is any colorectal cancer recurrence; follow-up 41 months to 64 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3520</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2877</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 1.06 (0.92 to 1.22)</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 80% (77% to 82%) relapse-free survival with more visits versus 81% with fewer<sup>6</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Local recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Distant metastasis</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Metachronous colorectal cancer</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Resectable recurrent disease (Salvage surgery; follow-up 41 months to 64 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>167/1034</p>
|
|
<p>(16.2%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>73/1007</p>
|
|
<p>(7.2%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 2.19 (1.71 to 2.81)</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 more per 1,000 (from 51 more to 131 more)</td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall quality of life (follow-up not reported)</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>4</sup><sup>,</sup><sup>5</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_15_1 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#ch17.s1.1.ref7" rid="ch17.s1.1.ref7">Kjeldsen 1997</a> (N=350) reported a small increase in quality of life, as measured by the Nottingham Health Profile, associated with more frequent follow-up visits compared with virtually no follow-up</td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_h_ch17.appf.tab2_1_1_2_3 hd_h_ch17.appf.tab2_1_1_2_4 hd_h_ch17.appf.tab2_1_1_2_5 hd_h_ch17.appf.tab2_1_1_2_6 hd_h_ch17.appf.tab2_1_1_2_7 hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_h_ch17.appf.tab2_1_1_2_9 hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_h_ch17.appf.tab2_1_1_2_11 hd_h_ch17.appf.tab2_1_1_1_4 hd_h_ch17.appf.tab2_1_1_1_5" id="hd_b_ch17.appf.tab2_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Procedure-related complications (Colonoscopy complications; follow-up 64 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_1 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_2 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_3 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>4</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_4 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_5 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_6 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_1 hd_h_ch17.appf.tab2_1_1_2_7 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_8 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3/1204</p>
|
|
<p>(0.2%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab2_1_1_1_2 hd_h_ch17.appf.tab2_1_1_2_9 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/357</p>
|
|
<p>(0.0%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_10 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 3.66 (0.25 to 54.28)</td><td headers="hd_h_ch17.appf.tab2_1_1_1_3 hd_h_ch17.appf.tab2_1_1_2_11 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 more per 1,000 (from 1 fewer to 51 more)<sup>7</sup></td><td headers="hd_h_ch17.appf.tab2_1_1_1_4 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch17.appf.tab2_1_1_1_5 hd_b_ch17.appf.tab2_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; HR: hazard ratio; OR: odds ratio; RR: relative risk</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch17.appf.tab2_1"><p class="no_margin">Downgraded 4 trials were not blinded which could cause ascertainment bias for cause of death.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch17.appf.tab2_2"><p class="no_margin">Downgraded because 3 trials were not blinded and 1 lacked allocation concealment.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch17.appf.tab2_3"><p class="no_margin">Number of events <300</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch17.appf.tab2_4"><p class="no_margin">Downgraded due to lack of blinding</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch17.appf.tab2_5"><p class="no_margin">HRQoL only measured in 350/597 participants in the trial</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch17.appf.tab2_6"><p class="no_margin">Control group rates take from <a class="bibr" href="#ch17.s1.1.ref3" rid="ch17.s1.1.ref3">COLOFOL 2018</a> trial</p></div></dd></dl><dl class="bkr_refwrap"><dt>7</dt><dd><div id="ch17.appf.tab2_7"><p class="no_margin">Assumed control group risk of 0.1%</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appftab3"><div id="ch17.appf.tab3" class="table"><h3><span class="label">Table 7</span><span class="title">Clinical evidence profile for comparison 3: Visits or tests versus minimal or no follow-up</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appf.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appf.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appf.tab3_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch17.appf.tab3_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch17.appf.tab3_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch17.appf.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab3_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch17.appf.tab3_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab3_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th headers="hd_h_ch17.appf.tab3_1_1_1_1" id="hd_h_ch17.appf.tab3_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other considerations</th><th headers="hd_h_ch17.appf.tab3_1_1_1_2" id="hd_h_ch17.appf.tab3_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Visits and tests</th><th headers="hd_h_ch17.appf.tab3_1_1_1_2" id="hd_h_ch17.appf.tab3_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Minimal or no follow-up</th><th headers="hd_h_ch17.appf.tab3_1_1_1_3" id="hd_h_ch17.appf.tab3_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relative (95% CI)</th><th headers="hd_h_ch17.appf.tab3_1_1_1_3" id="hd_h_ch17.appf.tab3_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Overall survival (event is death from any cause; follow-up 41 months to 66 weeks)</b>
|
|
</td></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1121</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">513</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.90 (0.64 to 1.26)</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 83% (77% to 87%) overall survival with visits & tests versus 81% with minimal follow-up<sup>4</sup></td><td headers="hd_h_ch17.appf.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer-specific survival (event is death from colorectal cancer; follow-up 41 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">954</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">355</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 1.01 (0.70 to 1.47)</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 87% (81% to 91%) cancer-specific survival with visits & tests versus 87% with minimal follow-up<sup>4</sup></td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Relapse-free survival (event is any colorectal cancer recurrence; follow-up 41 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1313</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">658</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.98 (0.67 to 1.44)</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 86% (80% to 91%) relapse-free survival with visits & tests versus 86% with minimal follow-up<sup>4</sup></td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Local recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Distant recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Metachronous colorectal cancer</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Resectablility of recurrent disease (Salvage surgery; follow-up 41 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>106/1313</p>
|
|
<p>(8.1%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>28/658</p>
|
|
<p>(4.3%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.98 (1.30 to 3.01)</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42 more per 1,000 (from 13 more to 86 more)</td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall quality of life</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_h_ch17.appf.tab3_1_1_2_3 hd_h_ch17.appf.tab3_1_1_2_4 hd_h_ch17.appf.tab3_1_1_2_5 hd_h_ch17.appf.tab3_1_1_2_6 hd_h_ch17.appf.tab3_1_1_2_7 hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_h_ch17.appf.tab3_1_1_2_9 hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_h_ch17.appf.tab3_1_1_2_11 hd_h_ch17.appf.tab3_1_1_1_4 hd_h_ch17.appf.tab3_1_1_1_5" id="hd_b_ch17.appf.tab3_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Procedure-related complications</th></tr><tr><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_1 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_2 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_3 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_4 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_5 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_6 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_1 hd_h_ch17.appf.tab3_1_1_2_7 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_8 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_2 hd_h_ch17.appf.tab3_1_1_2_9 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_10 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_3 hd_h_ch17.appf.tab3_1_1_2_11 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_4 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab3_1_1_1_5 hd_b_ch17.appf.tab3_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; HR: hazard ratio; RR: relative risk</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch17.appf.tab3_1"><p class="no_margin">Downgraded due to high risk of bias due to allocation concealment in one of the trials.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch17.appf.tab3_2"><p class="no_margin">Serious heterogeneity (I2 = 61%). Random effects model used, but there were no pre-specified subgroups to allow for further exploration of the causes of heterogeneity.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch17.appf.tab3_3"><p class="no_margin">Number of events <300</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch17.appf.tab3_4"><p class="no_margin">Control group rate taken from symptomatic follow-up only arm of <a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a> trial</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appftab4"><div id="ch17.appf.tab4" class="table"><h3><span class="label">Table 8</span><span class="title">Clinical evidence profile for comparison 4: More liver imaging versus less liver imaging</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appf.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appf.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appf.tab4_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch17.appf.tab4_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch17.appf.tab4_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch17.appf.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab4_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch17.appf.tab4_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab4_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th headers="hd_h_ch17.appf.tab4_1_1_1_1" id="hd_h_ch17.appf.tab4_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other considerations</th><th headers="hd_h_ch17.appf.tab4_1_1_1_2" id="hd_h_ch17.appf.tab4_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">More liver imaging</th><th headers="hd_h_ch17.appf.tab4_1_1_1_2" id="hd_h_ch17.appf.tab4_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">less liver imaging</th><th headers="hd_h_ch17.appf.tab4_1_1_1_3" id="hd_h_ch17.appf.tab4_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relative (95% CI)</th><th headers="hd_h_ch17.appf.tab4_1_1_1_3" id="hd_h_ch17.appf.tab4_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute (95% CI)</th></tr></thead><tbody><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall survival (event is death from any cause; follow-up 48 months to 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2957</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3804</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.87 (0.72 to 1.05)</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 81% (78% to 84%) overall survival with more imaging versus 79% with less<sup>4</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer-specific survival (event is death from colorectal cancer; follow-up 48 months to 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2790</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3659</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.88 (0.63 to 1.22)</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 88% (84% to 92%) cancer-specific survival with more imaging versus 87% with less<sup>4</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Relapse-free survival (event is any colorectal cancer recurrence; follow-up 48 months to 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">916</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">910</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 1.03 (0.76 to 1.41)</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 83% (77% to 87%) relapse-free survival with more imaging versus 83% with less<sup>4</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Local recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Distant recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Metachronous colorectal cancer</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Resectablility of recurrent disease (Salvage surgery; follow-up 48 months to 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>126/1517</p>
|
|
<p>(8.3%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>88/1509</p>
|
|
<p>(5.8%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.43 (1.10 to 1.86)</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25 more per 1,000 (from 6 more to 50 more)</td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall quality of life (follow-up 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_15_1 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;">No clinically important differences among the three main quality of life scales (SF-12 mental component, SF-12 physical component, and PGWB Index) between the two study arms (N=1228).</td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_h_ch17.appf.tab4_1_1_2_3 hd_h_ch17.appf.tab4_1_1_2_4 hd_h_ch17.appf.tab4_1_1_2_5 hd_h_ch17.appf.tab4_1_1_2_6 hd_h_ch17.appf.tab4_1_1_2_7 hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_h_ch17.appf.tab4_1_1_2_9 hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_h_ch17.appf.tab4_1_1_2_11 hd_h_ch17.appf.tab4_1_1_1_4 hd_h_ch17.appf.tab4_1_1_1_5" id="hd_b_ch17.appf.tab4_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Procedure-related complications</th></tr><tr><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_1 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_2 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_3 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_4 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_5 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_6 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_1 hd_h_ch17.appf.tab4_1_1_2_7 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_8 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_2 hd_h_ch17.appf.tab4_1_1_2_9 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_10 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_3 hd_h_ch17.appf.tab4_1_1_2_11 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_4 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab4_1_1_1_5 hd_b_ch17.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; HR: hazard ratio; PGWB Index: psychological general well-being index; RR: relative risk; SF-12: 12-Item Short Form Survey</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch17.appf.tab4_1"><p class="no_margin">Downgraded because 2 trials were at high risk of bias due to lack of allocation concealment</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch17.appf.tab4_2"><p class="no_margin">Number of participants <300</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch17.appf.tab4_3"><p class="no_margin">Unclear imprecision as no figures were presented in <a class="bibr" href="#ch17.s1.1.ref6" rid="ch17.s1.1.ref6">Jeffrey 2016</a></p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch17.appf.tab4_4"><p class="no_margin">Control group rates taken from no-CT arms of the <a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a> trial</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appftab5"><div id="ch17.appf.tab5" class="table"><h3><span class="label">Table 9</span><span class="title">Clinical evidence profile for comparison 5: CEA tests versus no CEA tests</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appf.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appf.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appf.tab5_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch17.appf.tab5_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch17.appf.tab5_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch17.appf.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab5_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch17.appf.tab5_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab5_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th headers="hd_h_ch17.appf.tab5_1_1_1_1" id="hd_h_ch17.appf.tab5_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other considerations</th><th headers="hd_h_ch17.appf.tab5_1_1_1_2" id="hd_h_ch17.appf.tab5_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">CEA</th><th headers="hd_h_ch17.appf.tab5_1_1_1_2" id="hd_h_ch17.appf.tab5_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">no CEA</th><th headers="hd_h_ch17.appf.tab5_1_1_1_3" id="hd_h_ch17.appf.tab5_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relative (95% CI)</th><th headers="hd_h_ch17.appf.tab5_1_1_1_3" id="hd_h_ch17.appf.tab5_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute (95% CI)</th></tr></thead><tbody><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall survival (event is death from any cause; follow-up 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">451</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">469</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.90 (0.70 to 1.16)</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 81% (76% to 85%) overall survival with CEA versus 79% with no CEA<sup>4</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer-specific survival (event is death from colorectal cancer; follow-up 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">343</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">361</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.93 (0.68 to 1.28)</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 88% (84% to 91%) cancer-specific survival with CEA versus 87% with no CEA<sup>4</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Relapse-free survival (event is any colorectal cancer recurrence; follow-up 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">451</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">469</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 0.91 (0.70 to 1.19)</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 5 years: 84% (80% to 88%) relapse-free survival with CEA versus 83% with no CEA<sup>4</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Local recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Distant recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Metachronous colorectal cancer</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Resectablility of recurrent disease (Salvage surgery; follow-up 41 months to 66 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>126/1053</p>
|
|
<p>(12.0%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>70/1067</p>
|
|
<p>(6.6%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.89 (1.12 to 3.20)</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 more per 1,000 (from 8 more to 144 more)</td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall quality of life</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_h_ch17.appf.tab5_1_1_2_3 hd_h_ch17.appf.tab5_1_1_2_4 hd_h_ch17.appf.tab5_1_1_2_5 hd_h_ch17.appf.tab5_1_1_2_6 hd_h_ch17.appf.tab5_1_1_2_7 hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_h_ch17.appf.tab5_1_1_2_9 hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_h_ch17.appf.tab5_1_1_2_11 hd_h_ch17.appf.tab5_1_1_1_4 hd_h_ch17.appf.tab5_1_1_1_5" id="hd_b_ch17.appf.tab5_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Procedure-related complications</th></tr><tr><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_1 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_2 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_3 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_4 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_5 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_6 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_1 hd_h_ch17.appf.tab5_1_1_2_7 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_8 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_2 hd_h_ch17.appf.tab5_1_1_2_9 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_10 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_3 hd_h_ch17.appf.tab5_1_1_2_11 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_4 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab5_1_1_1_5 hd_b_ch17.appf.tab5_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CEA: carcinoembryonic antigen; CI: confidence interval; HR: hazard ratio; RR: relative risk</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch17.appf.tab5_1"><p class="no_margin">One trial at high risk of bias due to lack of allocation concealment and blinding</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch17.appf.tab5_2"><p class="no_margin">Considerable heterogeneity (I2=64%). Random effects model used- but no subgroups were specified for exploration of heterogeneity.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch17.appf.tab5_3"><p class="no_margin">Number of events < 300</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch17.appf.tab5_4"><p class="no_margin">Control group rates taken from no-CEA arms of the <a class="bibr" href="#ch17.s1.1.ref4" rid="ch17.s1.1.ref4">FACS 2014</a> trial</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appftab6"><div id="ch17.appf.tab6" class="table"><h3><span class="label">Table 10</span><span class="title">Clinical evidence profile for comparison 6: Nurse or GP led follow-up versus surgeon led follow-up</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appf.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appf.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch17.appf.tab6_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch17.appf.tab6_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch17.appf.tab6_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch17.appf.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab6_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch17.appf.tab6_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch17.appf.tab6_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th headers="hd_h_ch17.appf.tab6_1_1_1_1" id="hd_h_ch17.appf.tab6_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other considerations</th><th headers="hd_h_ch17.appf.tab6_1_1_1_2" id="hd_h_ch17.appf.tab6_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Nurse or GP led</th><th headers="hd_h_ch17.appf.tab6_1_1_1_2" id="hd_h_ch17.appf.tab6_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Surgeonled</th><th headers="hd_h_ch17.appf.tab6_1_1_1_3" id="hd_h_ch17.appf.tab6_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Relative (95% CI)</th><th headers="hd_h_ch17.appf.tab6_1_1_1_3" id="hd_h_ch17.appf.tab6_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute (95% CI)</th></tr></thead><tbody><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall survival (event is death from any cause; follow-up: range 24 months to 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 1.39 (0.38 to 5.12)</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NR<sup>2</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer-specific survival (event is death from colorectal cancer; follow-up 24 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 3.46 (0.58 to 20.56)</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NR<sup>2</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Relapse-free survival (event is any colorectal cancer recurrence; follow-up 24 months to 60 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HR 1.07 (0.50 to 2.30)</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NR<sup>2</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Local recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Distant recurrence</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Metachronous colorectal cancer</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Resectablility of recurrent disease (Salvage surgery; follow-up 24 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4/55</p>
|
|
<p>(7.3%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3/55</p>
|
|
<p>(5.5%)</p>
|
|
</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.33 (0.31 to 5.68)</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 more per 1,000 (from 38 fewer to 255 more)</td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Overall quality of life (follow-up 24 months)</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">not serious</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_15_1 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#ch17.s1.1.ref1" rid="ch17.s1.1.ref1">Augestad 2013</a> (N=110) reported no significant effect on quality of life main outcome measures. For EORTC QLQ-C30, significant effects in favour of GP-led follow-up were reported for role functioning (P= 0.02), emotional functioning (P = 0.01), and pain (P = 0.01). <a class="bibr" href="#ch17.s1.1.ref18" rid="ch17.s1.1.ref18">Wattchow 2006</a> (N=203) found no important differences between HRQoL in primary versus secondary care follow-up.</td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_h_ch17.appf.tab6_1_1_2_3 hd_h_ch17.appf.tab6_1_1_2_4 hd_h_ch17.appf.tab6_1_1_2_5 hd_h_ch17.appf.tab6_1_1_2_6 hd_h_ch17.appf.tab6_1_1_2_7 hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_h_ch17.appf.tab6_1_1_2_9 hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_h_ch17.appf.tab6_1_1_2_11 hd_h_ch17.appf.tab6_1_1_1_4 hd_h_ch17.appf.tab6_1_1_1_5" id="hd_b_ch17.appf.tab6_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Procedure-related complications</th></tr><tr><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_1 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_2 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence available</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_3 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_4 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_5 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_6 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_1 hd_h_ch17.appf.tab6_1_1_2_7 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_8 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_2 hd_h_ch17.appf.tab6_1_1_2_9 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_10 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_3 hd_h_ch17.appf.tab6_1_1_2_11 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_4 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch17.appf.tab6_1_1_1_5 hd_b_ch17.appf.tab6_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items; GP: General Practitioner; HR: hazard ratio: HrQoL: Health-related Quality of Life; NR: not reported; RR: relative risk</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch17.appf.tab6_1"><p class="no_margin">Number of events <300</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch17.appf.tab6_2"><p class="no_margin">Insufficient information to calculate absolute survival rates</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch17appktab1"><div id="ch17.appk.tab1" class="table"><h3><span class="label">Table 11</span><span class="title">Excluded studies and reasons for their exclusion</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559930/table/ch17.appk.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch17.appk.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial) (Project record), Health Technology Assessment Database, 2005 [<a href="/pmc/articles/PMC5494506/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5494506</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28641703" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28641703</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HTA Database entry for the FACS trial</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Adams, K., Higgins, L., Beazley, S., Ryan, S., Papagrigoriadis, S., Efficacy of a nurse-led colorectal cancer follow-up clinic-long-term outcomes, Diseases of the Colon and Rectum, Conference, Annual Meeting of the American Society of Colon and Rectal Surgeons, ACSRS 2011. Vancouver, BC Canada. Conference Publication: (var.pagings). 54 (5) (pp e165), 2011
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non comparative study</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Andersson, P. H., Wille-Jorgensen, P., Horvath-Puho, E., Petersen, S. H., Martling, A., Sorensen, H. T., Syk, I., The COLOFOL trial: Study design and comparison of the study population with the source cancer population, Clinical Epidemiology, 8, 15–21, 2016 [<a href="/pmc/articles/PMC4734721/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4734721</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26869813" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26869813</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describes COLOFOL trial protocol</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Augestad, K. M., Norum, J., Dehof, S., Aspevik, R., Ringberg, U., Nestvold, T., Vonen, B., Skrovseth, S. O., Lindsetmo, R. O., Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: A randomised controlled trial, BMJ Open, 3 (4) (no pagination), 2013 [<a href="/pmc/articles/PMC3641467/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641467</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23564936" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23564936</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review.</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Augestad, K. M., Vonen, B., Aspevik, R., Nestvold, T., Ringberg, U., Johnsen, R., Norum, J., Lindsetmo, R. O., Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost-effectiveness and serious clinical events, BMC Health Services Research, 8, 2008 [<a href="/pmc/articles/PMC2474836/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2474836</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18578856" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18578856</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review.</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Baca, B., Beart
|
|
Jr, R. W., Etzioni, D. A., Surveillance after colorectal cancer resection: A systematic review, Diseases of the Colon and Rectum, 54, 1036–1048, 2011 [<a href="https://pubmed.ncbi.nlm.nih.gov/21730795" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21730795</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All relevant studies included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bastiaenen, V. P., Hovdenak
|
|
Jakobsen, I., Labianca, R., Martling, A., Morton, D. G., Primrose, J. N., Tanis, P. J., Laurberg, S., Consensus and controversies regarding follow-up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology, Colorectal Disease., 2019 [<a href="https://pubmed.ncbi.nlm.nih.gov/30506553" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30506553</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclude - summary of guidelines</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Belderbos, T. D., Leenders, M., Moons, L. M., Siersema, P. D., Local recurrence and timing of follow-up colonoscopy after emr for nonpedunculated colorectal lesions: Systematic review and meta-analysis, Gastrointestinal Endoscopy, Conference, Digestive Disease Week 2013, DDW 2013. Orlando, FL United States. Conference Publication: (var.pagings). 77 (5 SUPPL. 1) (pp AB535–AB536), 2013
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Belderbos, T., Leenders, M., Moons, L., Siersema, P., Local recurrence after EMR for non-pedunculated colorectal lesions: Systematic review and meta-analysis, United European Gastroenterology Journal, Conference, 21st United European Gastroenterology Week. Berlin Germany. Conference Publication: (var.pagings). 1 (1 SUPPL. 1) (pp A329), 2013
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Byung, W. M., Jun, W. U., Hong, Y. M., Role of regular follow-up after curative surgery for colorectal cancer, Hepato Gastroenterology, 54, 63–66, 2007 [<a href="https://pubmed.ncbi.nlm.nih.gov/17419232" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17419232</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Coebergh Van Den Braak, R. R. J., Lalmahomed, Z. S., Buttner, S., Hansen, B. E., Ijzermans, J. N. M., Nonphysician Clinicians in the Follow-Up of Resected Patients with Colorectal Cancer, Digestive Diseases, 36, 17–25, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/28965109" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28965109</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an RCT</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Figueredo, A., Rumble, R. B., Maroun, J., Earle, C. C., Cummings, B., McLeod, R., Zuraw, L., Zwaal, C., Agboola, O., Citron, M., DeNardi, F. G., Fine, S., Fisher, B., Germond, C., Jonker, D., Khoo, K., Kocha, W., Lethbridge, M., Lofters, W., Malthaner, R., Moore, M., Tandan, V., Wong, R., Follow-up of patients with curatively resected colorectal cancer: A practice guideline, BMC Cancer, 3, 2003 [<a href="/pmc/articles/PMC270033/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC270033</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14529575" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14529575</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All relevant studies included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gage, M. M., Hueman, M. T., Colorectal Cancer Surveillance: What Is the Optimal Frequency of Follow-up and Which Tools Best Predict Recurrence?, Current Colorectal Cancer Reports, 13, 316–324, 2017
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Expert review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Grossmann, E. M., Johnson, F. E., Virgo, K. S., Longo, W. E., Fossati, R., Follow-up of colorectal cancer patients after resection with curative intent - The GILDA trial, Surgical Oncology, 13, 119–124, 2004 [<a href="https://pubmed.ncbi.nlm.nih.gov/15572094" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15572094</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review.</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Jeffery, G. M., Hickey, B. E., Hider, P., Follow-up strategies for patients treated for non-metastatic colorectal cancer, Cochrane Database of Systematic Reviews, 1, 2002 [<a href="https://pubmed.ncbi.nlm.nih.gov/11869629" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11869629</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Earlier version of Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Jeyarajah, S., Adams, K. J., Higgins, L., Ryan, S., Leather, A. J. M., Papagrigoriadis, S., Prospective evaluation of a colorectal cancer nurse follow- up clinic, Colorectal DiseaseColorectal Dis, 13, 31–38, 2011 [<a href="https://pubmed.ncbi.nlm.nih.gov/19674021" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19674021</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an RCT</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lee-Ying, R. M., Kennecke, H. F., Nguyen, L., Cheung, W. Y., Cost-effectiveness of surveillance after curative resection (CR) of metastatic colorectal cancer (CRC), Journal of Clinical Oncology, Conference, 2017 Gastrointestinal Cancers Symposium. United States. 35 (4 Supplement 1) (no pagination), 2017
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lepage, C, Phelip, J-M, Cany, L, Maillard, E, Lievre, A, Chatellier, T, Faroux, R, Duchmann, J-C, Ben, Abdelghani
|
|
M, Breysacher, G, Geoffroy, P, Pere-Verge, D, Pelaquier, A, Pillon, D, Ezenfis, J, Rinaldi, Y, Darut-Jouve, A, Duluc, M, Adenis, A, Bouche, O, Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer-PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics, Annals of oncology. Conference: 41st european society for medical oncology congress, ESMO 2016. Denmark. Conference start: 20161007. Conference end: 20161011, 27, 2016
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ongoing trial, abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lopez-Kostner, F., Zarate, A., Kronberg, U., Sanguineti, A., Pinto, E., Wainstein, C., Long-term functional and oncologic outcome in patients undergoing intersphincteric resection with handsewn coloanal anastomosis for very low rectal cancer, Diseases of the Colon and Rectum, Conference, Annual Meeting of the American Society of Colon and Rectal Surgeons, ACSRS 2011. Vancouver, BC Canada. Conference Publication: (var.pagings). 54 (5) (pp e170), 2011
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mant, D, Perera, R, Gray, A, Rose, P, Fuller, A, Corkhill, A, George, S, Little, L, Regan, S, Mellor, J, Pugh, Sa, Northover, J, Weaver, A, Barsoum, G, Tan, Lt, Mortensen, N, Scholefield, J, Wasan, H, Ferry, D, Primrose, Jn, Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial, Journal of Clinical Oncology, 31, 2013 [<a href="https://pubmed.ncbi.nlm.nih.gov/24430319" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24430319</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FACS trial 5 year resultsâ□” already included in Cochrane Review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mant, D., Gray, A., Pugh, S., Campbell, H., George, S., Fuller, A., Shinkins, B., Corkhill, A., Mellor, J., Dixon, E., Little, L., PereraSalazar, R., Primrose, J., A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent, Health Technology Assessment, 21, 2017 [<a href="/pmc/articles/PMC5494506/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5494506</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28641703" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28641703</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FACS trial 5 year resultsâ□” already included in Cochrane Review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mercado, M., Hart, R., Scheer, A., Tricco, A., Hamid, J., Brezden-Masley, C., Impact of CEA alone or as part of a high intensity surveillance strategy in detecting curative colorectal cancer recurrence: A systematic review and meta-analysis, Journal of Clinical Oncology, Conference, 2017 Gastrointestinal Cancers Symposium. United States. 35 (4 Supplement 1) (no pagination), 2017
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mokhles, S., Macbeth, F., Farewell, V., Fiorentino, F., Williams, N. R., Younes, R. N., Takkenberg, J. J., Treasure, T., Meta-analysis of colorectal cancer follow-up after potentially curative resection, British Journal of Surgery, 103, 1259–68, 2016 [<a href="/pmc/articles/PMC5031212/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5031212</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27488593" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27488593</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevant included studies are reported in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Papagrigoriadis, S., Follow-up of patients with colorectal cancer: The evidence is in favour but we are still in need of a protocol, International Journal of Surgery, 5, 120–128, 2007 [<a href="https://pubmed.ncbi.nlm.nih.gov/17448977" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17448977</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All relevant studies included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Patel, K., Hadar, N., Lee, J., Siegel, B. A., Hillner, B. E., Lau, J., The Lack of Evidence for PET or PET/CT Surveillance of Patients with Treated Lymphoma, Colorectal Cancer, and Head and Neck Cancer: A Systematic Review, Journal of Nuclear MedicineJ Nucl Med, 54, 1518–1527, 2013 [<a href="/pmc/articles/PMC3980728/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3980728</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23776200" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23776200</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Only diagnostic accuracy data are presented</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pita-Fernandez, S, Alhayek-Ai, M, Gonzalez-Martin, C, Lopez-Calvino, B, Seoane-Pillado, T, Pertega-Diaz, S, Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis (Provisional abstract), Database of Abstracts of Reviews of Effects, epub, 2014
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DARE database entry for Pita-Fernandez 2015</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pita-Fernandez, S., Alhayek-Ai, M., Gonzalez-Martin, C., Lopez-Calvino, B., Seoane-Pillado, T., Pertega-Diaz, S., Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: A systematic review and meta-analysis, Annals of OncologyAnn Oncol, 26, 644–656, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/25411419" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25411419</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevant included studies are reported in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Primrose, J. N., Fuller, A., Rose, P., Perera-Salazar, R., Mellor, J., Corkhill, A., George, S., Mant, D., Follow-up after colorectal cancer surgery: Preliminary observational findings from the UK FACS trial, Journal of Clinical Oncology, Conference, ASCO Annual Meeting 2011. Chicago, IL United States. Conference Publication: (var.pagings). 29 (15 SUPPL. 1) (no pagination), 2011
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Primrose, J. N., Perera, R., Gray, A., Effect of 3 to 5 years of scheduled CEA and CT followup to detect recurrence of colorectal cancer: The FACS randomized clinical trial, Diseases of the Colon and Rectum, 57, e421–e422, 2014 [<a href="https://pubmed.ncbi.nlm.nih.gov/24430319" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24430319</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Primrose, Jn, Perera, R, Gray, A, Rose, P, Fuller, A, Corkhill, A, George, S, Mant, D, Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial, Jama, 311, 263–270, 2014 [<a href="https://pubmed.ncbi.nlm.nih.gov/24430319" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24430319</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pugh, S. A., Fuller, A., Perera, R., George, S., Mant, D., Primrose, J., The follow-up after colorectal cancer surgery trial: Randomised trial of follow-up after colorectal cancer surgery and outcome following recurrence, Journal of the American College of Surgeons, 1), e46–e47, 2014
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pugh, S. A., Mant, D., Shinkins, B., Mellor, J., Perera, R., Primrose, J., Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial, Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO, 27, 2016
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract of FACS trial 8 year results, insufficient detail to extract survival data</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Renehan, A. G., Egger, M., Saunders, M. P., O’Dwyer, S. T., Impact on survival of intensive follow up after curative resection for colorectal cancer: Systematic review and meta-analysis of randomised trials, British Medical Journal, 324, 813–816, 2002 [<a href="/pmc/articles/PMC100789/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC100789</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11934773" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11934773</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All relevant studies reported in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rodriguez-Moranta, F, Castells, A, Salo, J, Arcusa, A, Boadas, J, Besssa, V, Pinol, V, Balaguer, F, Cuardrado, R, Delgado, S, Lacy, A, Batiste-Alentorn, E, Pique, Jm, Efficacy Of Postoperative Surveillance After Radical Surgery for Colorectal Cancer (CRC). Analysis Of a Prospective, Multicenter, Randomized Controlled Trial, Journal of Gastroenterology, 128, Abstract W967, 2005
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in the Jeffrey 2016 Cochrane Review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rodriguez-Moranta, F., Salo, J., Arcusa, A., Boadas, J., Pinol, V., Bessa, X., Batiste-Alentorn, E., Lacy, A. M., Delgado, S., Maurel, J., Pique, J. M., Castells, A., Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective, multicenter, randomized, controlled trial, Journal of Clinical Oncology, 24, 386–393, 2006 [<a href="https://pubmed.ncbi.nlm.nih.gov/16365182" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16365182</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Already included in Jeffrey 2016 systematic review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rosati, G., Ambrosini, G., Barni, S., Andreoni, B., Corradini, G., Luchena, G., Daniele, B., Gaion, F., Oliverio, G., Duro, M., Martignoni, G., Pinna, N., Sozzi, P., Pancera, G., Solina, G., Pavia, G., Pignata, S., Johnson, F., Labianca, R., Apolone, G., Zaniboni, A., Monteforte, M., Negri, E., Torri, V., Mosconi, P., Fossati, R., A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma, Annals of Oncology, 27, 274–280, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26578734" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26578734</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GILDA trial - already included in Jeffrey 2016 Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Secco, G. B., Fardelli, R., Gianquinto, D., Bonfante, P., Baldi, E., Ravera, G., Derchi, L., Ferraris, R., Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: A prospective, randomized and controlled trial, European Journal of Surgical Oncology, 28, 418–423, 2002 [<a href="https://pubmed.ncbi.nlm.nih.gov/12099653" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12099653</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Shinkins, B., Nicholson, B. D., James, T., Pathiraja, I., Pugh, S., Perera, R., Primrose, J., Mant, D., What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial, Health Technology Assessment, 21, 2017 [<a href="/pmc/articles/PMC5483644/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5483644</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28617240" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28617240</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Secondary analysis of FACS trial</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sobhani, I, Baumgaertner, I, Tounigand, C, Ette, E, Brunetti, F, Gagniere, C, Luciani, A, Durand-Zaleski, I, Bastuji-Garin, S, Follow-up of colorectal cancer (CRC) patients including 18FDGPET-CT (PET-CT): an open-label multicenter randomized trial (clinical trial: NCT 00624260), United european gastroenterology journal. Conference: 25th united european gastroenterology week, UEG 2017. Spain, 5, A13, 2017
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract relating to <a class="bibr" href="#ch17.s1.1.ref14" rid="ch17.s1.1.ref14">Sobhani 2008</a> trial (which was included in Jeffrey 2016 Cochrane review)</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sobhani, I., Tiret, E., Lebtahi, R., Aparicio, T., Itti, E., Montravers, F., Vaylet, C., Rougier, P., Andre, T., Gornet, J. M., Cherqui, D., Delbaldo, C., Panis, Y., Talbot, J. N., Meignan, M., Le Guludec, D., Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer, British Journal of Cancer, 98, 875–80, 2008 [<a href="/pmc/articles/PMC2266857/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2266857</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18301402" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18301402</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Strand, E., Nygren, I., Bergkvist, L., Smedh, K., Nurse or surgeon follow-up after rectal cancer: a randomized trial, Colorectal Disease, 13, 999–1003, 2011 [<a href="https://pubmed.ncbi.nlm.nih.gov/20478003" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20478003</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Tjandra, J. J., Chan, M. K. Y., Follow-up after curative resection of colorectal cancer: A meta-analysis, Diseases of the Colon and Rectum, 50, 1783–1799, 2007 [<a href="https://pubmed.ncbi.nlm.nih.gov/17874269" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17874269</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verberne, C. J., Nijboer, C. H., de Bock, G. H., Grossmann, I., Wiggers, T., Havenga, K., Evaluation of the use of decision-support software in carcino-embryonic antigen (CEA)-based follow-up of patients with colorectal cancer, BMC medical informatics and decision making, 12, 2012 [<a href="/pmc/articles/PMC3330015/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3330015</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22390356" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22390356</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCLUDE(not an RCT)</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verberne, C. J., Wiggers, T., Grossmann, I., de Bock, G. H., Vermeulen, K. M., Cost-effectiveness of a carcinoembryonic antigen (CEA) based follow-up programme for colorectal cancer (the CEA Watch trial), Colorectal DiseaseColorectal Dis, 18, O91–O96, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26757353" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26757353</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verberne, C. J., Zhan, Z., Van Den Heuvel, E., Grossmann, I., Doornbos, P. M., Havenga, K., Manusama, E., Klaase, J., Van Der Mijle, H. C. J., Lamme, B., Bosscha, K., Baas, P., Van Ooijen, B., Nieuwenhuijzen, G., Marinelli, A., Van Der Zaag, E., Wasowicz, D., De Bock, G. H., Wiggers, T., Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: Results of the randomized “CEAwatch” trial, European Journal of Surgical OncologyEur J Surg Oncol, 41, 1188–1196, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/26184850" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26184850</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Earlier publication of CEAwatch trial (see <a class="bibr" href="#ch17.s1.1.ref2" rid="ch17.s1.1.ref2">Verberne 2017</a>)</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verberne, C., Doornbos, P. M., Grossmann, I., De Bock, G. H., Wiggers, T., Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging, European Journal of Cancer, Conference, European Cancer Congress 2013, ECC 2013. Amsterdam Netherlands. Conference Publication: (var.pagings). 49 (SUPPL. 2) (pp S480), 2013
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verberne, C., Van Den Heuvel, E., De Bock, G. H., Grossmann, I., Wiggers, T., Intensified Follow-up in Colorectal Cancer Patients using Frequent Carcinoembryonic (CEA) Measurements and CEA-triggered Imaging, Annals of Surgical Oncology, Conference, 67th Annual Cancer Symposium of the Society of Surgical Oncology. Phoenix, AZ United States. Conference Publication: (var.pagings). 21 (1 SUPPL. 1) (pp S6), 2014
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verberne, C., Zhan, Z., De Bock, G., Wiggers, T., Intensifying colorectal cancer follow-up - Survival analysis of the randomized multicenter CEAwatch trial, European Journal of Surgical OncologyEur J Surg Oncol, 42 (9), S106, 2016
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wang, T., Cui, Y., Huang, W. S., Deng, Y. H., Gong, W., Li, C. j, Wang, J. P., The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study, Gastrointestinal Endoscopy, 69, 609–615, 2009 [<a href="https://pubmed.ncbi.nlm.nih.gov/19136105" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19136105</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wattchow, Da, Weller, Dp, Esterman, A, Pilotto, Ls, McGorm, K, Hammett, Z, Platell, C, Silagy, C, General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial, British Journal of Cancer, 94, 1116–1121, 2006 [<a href="/pmc/articles/PMC2361245/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2361245</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16622437" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16622437</span></a>]
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane review</td></tr><tr><td headers="hd_h_ch17.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wille-Jorgensen, P, Syk, I, Smedh, K, Laurberg, S, Nielsen, Dt, Pahlman, L, Petersen, Sh, Sorensen, Ht, Renehan, A, Intensity of follow up after surgery for colorectal cancer, Colorectal disease., 16, 93, 2014
|
|
</td><td headers="hd_h_ch17.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Early conference abstract of COLOFOL trial</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|